1
|
Arslan A, Özkaya ÖG, Aytemiz F, Altay H, Özcan EE, Küçükaksu DS, Bakuy V, Kozan Ö, Pehlivanoğlu S. Oral amiodarone and propranolol in maintenance therapy of postimplantation tachycardia: An observational study. Medicine (Baltimore) 2024; 103:e38839. [PMID: 38996090 PMCID: PMC11245262 DOI: 10.1097/md.0000000000038839] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/03/2024] [Accepted: 06/14/2024] [Indexed: 07/14/2024] Open
Abstract
Left ventricular assist devices (LVADs) are widely used as end-stage therapy in patients with advanced heart failure, whereas implantation increases the risks of development of sustained ventricular tachycardia at the later postimplantation stage. Therefore, this study aimed to evaluate the clinical efficacy of orally administered amiodarone and propranolol in 3 patients with ventricular tachycardia (VT) after LVAD implantation who were resistant to initial anti-antiarrhythmic drugs. This retrospective cohort study consisted of the initial evaluation of the clinical data of 14 adult patients who underwent implantation of LVAD between January 2019 and March 2021. A total of 3 patients with resistant VT were finally included. In all cases, the patients were initially administered amiodarone in the different doses intravenously to stabilize the critical condition, whereas its oral form along with that of propranolol was used as maintenance therapy in the first 2 cases. In the third case, amiodarone was withdrawn because of the risk of development of hyperthyroidism, while oral propranolol was used in the treatment. The assessment in the 16-month follow-up period after discharge did not show presence of non-sustained and sustained VT in all 3 cases. In the ventricular arrhythmia-free group, the total mortality rate within the follow-up period was 11.1 ± 7.78 months in the 3 patients. We suggest that maintenance oral therapy of propranolol and amiodarone can significantly decrease the risks of complications in patients with VT after implantation of ventricular assist device in the long term.
Collapse
Affiliation(s)
- Abdulla Arslan
- Cardiology Department, Baskent University Istanbul Medical and Research Center, Altunizade/Istanbul, Turkey
| | - Öykü Gülmez Özkaya
- Cardiology Department, Baskent University Istanbul Medical and Research Center, Altunizade/Istanbul, Turkey
| | - Fatih Aytemiz
- Cardiology Department, Manisa State Hospital, Manisa, Turkey
| | - Hakan Altay
- Cardiology Department, Baskent University Istanbul Medical and Research Center, Altunizade/Istanbul, Turkey
| | - Emin Evren Özcan
- Cardiology Department, Dokuz Eylül University Izmir Medical and Research Center, Balçova/Izmir, Turkey
| | - Deniz Süha Küçükaksu
- Cardiovascular Surgery Department, Baskent University Istanbul Medical and Research Center, Altunizade/Istanbul, Turkey
| | - Vedat Bakuy
- Cardiovascular Surgery Department, Baskent University Istanbul Medical and Research Center, Altunizade/Istanbul, Turkey
| | - Ömer Kozan
- Cardiology Department, Baskent University Istanbul Medical and Research Center, Altunizade/Istanbul, Turkey
| | - Seçkin Pehlivanoğlu
- Cardiology Department, Baskent University Istanbul Medical and Research Center, Altunizade/Istanbul, Turkey
| |
Collapse
|
2
|
Lynch PT, Maloof A, Badjatiya A, Safavi-Naeini P, Segar MW, Kim JA, Marashly Q, Molina-Razavi JE, Simpson L, Oberton SB, Xie LX, Civitello A, Mathuria N, Cheng J, Rasekh A, Saeed M, Razavi M, Nair A, Chelu MG. Mortality in Recipients of Durable Left Ventricular Assist Devices Undergoing Ventricular Tachycardia Ablation. JACC Clin Electrophysiol 2024:S2405-500X(24)00457-2. [PMID: 39023485 DOI: 10.1016/j.jacep.2024.04.037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2023] [Revised: 04/25/2024] [Accepted: 04/27/2024] [Indexed: 07/20/2024]
Abstract
BACKGROUND Left ventricular assist device (LVAD) recipients have a higher incidence of ventricular tachycardia (VT). However, the role of VT ablation in this population is not well-established. OBJECTIVES This single-center retrospective cohort study sought to examine the impact of post-LVAD implant VT ablation on survival. METHODS This retrospective study examined a cohort of patients that underwent LVAD implantation at Baylor St. Luke's Medical Center and Texas Heart Institute between January 2011 and January 2021. All-cause estimated mortality was compared across LVAD recipients based on the incidence of VT, timing of VT onset, and the occurrence and timing of VT ablation utilizing Kaplan-Meier survival analysis and Cox proportional hazards models. RESULTS Post-implant VT occurred in 53% of 575 LVAD recipients. Higher mortality was seen among patients with post-implant VT within a year of implantation (HR: 1.62 [95% CI: 1.15-2.27]). Among this cohort, patients who were treated with a catheter ablation had superior survival compared with patients treated with medical therapy alone for the 45 months following VT onset (HR: 0.48 [95% CI: 0.26-0.89]). Moreover, performance of an ablation in this population aligned mortality rates with those who did not experience post-implant VT (HR: 1.18 [95% CI: 0.71-1.98]). CONCLUSIONS VT occurrence within 1 year of LVAD implantation was associated with worse survival. However, performance of VT ablation in this population was correlated with improved survival compared with medical management alone. Among patients with refractory VT, catheter ablation aligned survival with other LVAD participants without post-implant VT. Catheter ablation of VT is associated with improved survival in LVAD recipients, but further prospective randomized studies are needed to compare VT ablation to medical management in LVAD recipients.
Collapse
Affiliation(s)
- Patrick T Lynch
- Department of Internal Medicine, Baylor College of Medicine, Houston, Texas, USA.
| | - Alexandra Maloof
- Department of Internal Medicine, Baylor College of Medicine, Houston, Texas, USA
| | - Anish Badjatiya
- Department of Medicine (Division of Cardiology), Baylor College of Medicine, Houston, Texas, USA
| | - Payam Safavi-Naeini
- Department of Medicine (Division of Cardiology), Baylor College of Medicine, Houston, Texas, USA
| | - Matthew W Segar
- Department of Medicine (Division of Cardiology), Baylor College of Medicine, Houston, Texas, USA; Texas Heart Institute, Houston, Texas, USA
| | - Jitae A Kim
- Division of Cardiovascular Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, USA
| | - Qussay Marashly
- Department of Cardiology, Montefiore Medical Center, New York, New York, USA
| | - Joanna E Molina-Razavi
- Department of Medicine (Division of Cardiology), Baylor College of Medicine, Houston, Texas, USA; Texas Heart Institute, Houston, Texas, USA
| | - Leo Simpson
- Department of Medicine (Division of Cardiology), Baylor College of Medicine, Houston, Texas, USA; Texas Heart Institute, Houston, Texas, USA
| | - Selby B Oberton
- Department of Medicine (Division of Cardiology), Baylor College of Medicine, Houston, Texas, USA; Texas Heart Institute, Houston, Texas, USA
| | - Lola X Xie
- Department of Medicine (Division of Cardiology), Baylor College of Medicine, Houston, Texas, USA; Texas Heart Institute, Houston, Texas, USA
| | - Andrew Civitello
- Department of Medicine (Division of Cardiology), Baylor College of Medicine, Houston, Texas, USA; Texas Heart Institute, Houston, Texas, USA; Cardiovascular Research Institute, Baylor College of Medicine, Houston, Texas, USA
| | - Nilesh Mathuria
- Department of Medicine (Division of Cardiology), Baylor College of Medicine, Houston, Texas, USA
| | - Jie Cheng
- Department of Medicine (Division of Cardiology), Baylor College of Medicine, Houston, Texas, USA; Texas Heart Institute, Houston, Texas, USA
| | - Abdi Rasekh
- Department of Medicine (Division of Cardiology), Baylor College of Medicine, Houston, Texas, USA; Texas Heart Institute, Houston, Texas, USA; Cardiovascular Research Institute, Baylor College of Medicine, Houston, Texas, USA
| | - Mohammad Saeed
- Department of Medicine (Division of Cardiology), Baylor College of Medicine, Houston, Texas, USA; Texas Heart Institute, Houston, Texas, USA; Cardiovascular Research Institute, Baylor College of Medicine, Houston, Texas, USA
| | - Mehdi Razavi
- Department of Medicine (Division of Cardiology), Baylor College of Medicine, Houston, Texas, USA; Texas Heart Institute, Houston, Texas, USA; Cardiovascular Research Institute, Baylor College of Medicine, Houston, Texas, USA
| | - Ajith Nair
- Department of Medicine (Division of Cardiology), Baylor College of Medicine, Houston, Texas, USA; Texas Heart Institute, Houston, Texas, USA; Cardiovascular Research Institute, Baylor College of Medicine, Houston, Texas, USA
| | - Mihail G Chelu
- Department of Medicine (Division of Cardiology), Baylor College of Medicine, Houston, Texas, USA; Texas Heart Institute, Houston, Texas, USA; Cardiovascular Research Institute, Baylor College of Medicine, Houston, Texas, USA.
| |
Collapse
|
3
|
Rordorf R, Pignalosa L, Casula M, Perna E, Baroni M, Garascia A, Guida S, Gazzoli F, Pini D, Cannata F, Pellegrino M, Vittori C, De Filippo P, Malanchini G, Vergara P, Della Bella P, Gulletta S. Real-world data of patients affected by advanced heart failure treated with implantable cardioverter defibrillator and left ventricular assist device: Results of a multicenter observational study. Artif Organs 2024; 48:525-535. [PMID: 38213270 DOI: 10.1111/aor.14708] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2023] [Revised: 11/16/2023] [Accepted: 12/26/2023] [Indexed: 01/13/2024]
Abstract
BACKGROUND Left ventricular assist device (L-VAD) implantation is increasingly used in patients with heart failure (HF) and most patients also have an implantable cardioverter defibrillator (ICD). Limited data are available on the incidence of ICD therapies and complications in this special setting. The aim of this study was to analyze the real-world incidence and predictors of ICD therapies, complications and interactions between ICD and L-VAD. METHODS We conducted a multicenter retrospective observational study in patients with advanced HF implanted with ICD and a continuous-flow L-VAD, followed-up in five advanced HF centers in Northern Italy. RESULTS A total of 234 patients (89.7% male, median age 59, 48.3% with ischemic etiology) were enrolled. After a median follow-up of 21 months, 66 patients (28.2%) experienced an appropriate ICD therapy, 22 patients (9.4%) an inappropriate ICD therapy, and 17 patients (7.3%) suffered from an interaction between ICD and L-VAD. The composite outcome of all ICD-related complications was reported in 41 patients (17.5%), and 121 (51.7%) experienced an L-VAD-related complication. At multivariable analysis, an active ventricular tachycardia (VT) zone and a prior ICD generator replacement were independent predictors of ICD therapies and of total ICD-related complications, respectively. CONCLUSIONS Real-world patients with both L-VAD and ICD experience a high rate of ICD therapies and complications. Our findings suggest the importance of tailoring device programming in order to minimize the incidence of unnecessary ICD therapies, thus sparing the need for ICD generator replacement, a procedure associated to a high risk of complications.
Collapse
Affiliation(s)
- Roberto Rordorf
- Arrhythmia and Electrophysiology Unit, IRCCS Fondazione Policlinico S. Matteo, Pavia, Italy
| | - Leonardo Pignalosa
- Arrhythmia and Electrophysiology Unit, IRCCS Fondazione Policlinico S. Matteo, Pavia, Italy
| | - Matteo Casula
- Arrhythmia and Electrophysiology Unit, IRCCS Fondazione Policlinico S. Matteo, Pavia, Italy
| | - Enrico Perna
- De Gasperis CardioCenter, Niguarda Hospital, Milan, Italy
| | - Matteo Baroni
- De Gasperis CardioCenter, Niguarda Hospital, Milan, Italy
| | | | - Stefania Guida
- Division of Cardiology, IRCCS Policlinico S. Matteo, Pavia, Italy
| | - Fabrizio Gazzoli
- Division Cardiac Surgery, IRCCS Policlinico S. Matteo, Pavia, Italy
| | - Daniela Pini
- Department of Perioperative Cardiology and Cardiovascular imaging, Centro Cardiologico Monzino IRCCS, Milan, Italy
| | - Francesco Cannata
- Department of Perioperative Cardiology and Cardiovascular imaging, Centro Cardiologico Monzino IRCCS, Milan, Italy
- Department of Biomedical Sciences, Humanitas University, Milan, Italy
| | - Marta Pellegrino
- Department of Perioperative Cardiology and Cardiovascular imaging, Centro Cardiologico Monzino IRCCS, Milan, Italy
| | - Claudia Vittori
- Division of Cardiology, Ospedale Giovanni XXIII, Bergamo, Italy
| | | | | | - Pasquale Vergara
- Department of Cardiac Electrophysiology and Arrhythmology, IRCCS San Raffaele University Hospital, Milan, Italy
| | - Paolo Della Bella
- Department of Cardiac Electrophysiology and Arrhythmology, IRCCS San Raffaele University Hospital, Milan, Italy
| | - Simone Gulletta
- Department of Cardiac Electrophysiology and Arrhythmology, IRCCS San Raffaele University Hospital, Milan, Italy
| |
Collapse
|
4
|
Soni B, Gopinathannair R. Managing ventricular arrhythmias and implantable cardiac defibrillator shocks after left ventricular assist device implantation. J Cardiovasc Electrophysiol 2024; 35:592-600. [PMID: 38013210 DOI: 10.1111/jce.16142] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/22/2023] [Revised: 11/13/2023] [Accepted: 11/14/2023] [Indexed: 11/29/2023]
Abstract
Continuous flow left ventricular assist devices (CF-LVADs) have been shown to reduce mortality and morbidity in patients with advanced heart failure with reduced ejection fraction. However, ventricular arrhythmias (VA) are common, are mostly secondary to underlying myocardial scar, and have a higher incidence in patients with pre-LVAD VA. Sustained VA is well tolerated in the LVAD patient but can result in implantable defibrillator (ICD) shocks, right ventricular failure, hospitalizations, and reduced quality of life. There is limited data regarding best practices for the medical management of VA as well as the role for procedural interventions in patients with uncontrolled VA and/or ICD shocks. Vast majority of CF-LVAD patients have a preexisting cardiovascular implantable electronic device (CIED) and ICD and/or cardiac resynchronization therapies are continued in many. Several questions, however, remain regarding the efficacy of ICD and CRT following CF-LVAD. Moreover, optimal CIED programming after CF-LVAD implantation. Therefore, the primary objective of this review article is to provide the most up-to-date evidence and to provide guidance on the clinical significance, pathogenesis, predictors, and management strategies for VA and ICD therapies in the CF-LVAD population. We also discuss knowledge gaps as well as areas for future research.
Collapse
Affiliation(s)
- Bosky Soni
- Department of Medicine, University of Pittsburgh School of Medicine, Harrisburg, Pennsylvania, USA
| | | |
Collapse
|
5
|
Benali K, Lloyd MS, Petrosyan A, Rigal L, Quivrin M, Bessieres I, Vlachos K, Hammache N, Bellec J, Simon A, Laurent G, Higgins K, Garnier F, de Crevoisier R, Martins R, Da Costa A, Guenancia C. Cardiac stereotactic radiation therapy for refractory ventricular arrhythmias in patients with left ventricular assist devices. J Cardiovasc Electrophysiol 2024; 35:206-213. [PMID: 38018417 DOI: 10.1111/jce.16139] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/11/2023] [Revised: 11/06/2023] [Accepted: 11/10/2023] [Indexed: 11/30/2023]
Abstract
Left ventricular assist device (LVAD) implantation is an established treatment for patients with advanced heart failure refractory to medical therapy. However, the incidence of ventricular arrhythmias (VAs) is high in this population, both in the acute and delayed phases after implantation. About one-third of patients implanted with an LVAD will experience sustained VAs, predisposing these patients to worse outcomes and complicating patient management. The combination of pre-existing myocardial substrate and complex electrical remodeling after LVAD implantation account for the high incidence of VAs observed in this population. LVAD patients presenting VAs refractory to antiarrhythmic therapy and catheter ablation procedures are not rare. In such patients, treatment options are extremely limited. Stereotactic body radiation therapy (SBRT) is a technique that delivers precise and high doses of radiation to highly defined targets, reducing exposure to adjacent normal tissue. Cardiac SBRT has recently emerged as a promising alternative with a growing number of case series reporting the effectiveness of the technique in reducing the VA burden in patients with arrhythmias refractory to conventional therapies. The safety profile of cardiac SBRT also appears favorable, even though the current clinical experience remains limited. The use of cardiac SBRT for the treatment of refractory VAs in patients implanted with an LVAD are even more scarce. This review summarizes the clinical experience of cardiac SBRT in LVAD patients and describes technical considerations related to the implementation of the SBRT procedure in the presence of an LVAD.
Collapse
Affiliation(s)
- Karim Benali
- Department of Cardiac Electrophysiology, Saint-Etienne University Hospital Center, Saint-Etienne, France
- Department of Signal Analysis, IHU LIRYC, Electrophysiology and Heart Modelling Institute, Bordeaux University, Bordeaux, France
- LTSI-UMR 1099, Rennes, France
| | - Michael S Lloyd
- Department of Cardiology, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Andranik Petrosyan
- Department of Cardiac Surgery, Saint-Etienne University Hospital Center, Saint-Etienne, France
| | - Louis Rigal
- Department of Signal Analysis, IHU LIRYC, Electrophysiology and Heart Modelling Institute, Bordeaux University, Bordeaux, France
| | - Magali Quivrin
- Department of Radiation Oncology, Centre Georges Francois Leclerc, Dijon, France
| | - Igor Bessieres
- Department of Radiation Oncology, Centre Georges Francois Leclerc, Dijon, France
| | | | - Nefissa Hammache
- Department of Cardiac Electrophysiology, Nancy University Hospital Center, Nancy, France
| | - Julien Bellec
- Department of Radiation Oncology, Centre Eugene Marquis, Rennes, France
| | - Antoine Simon
- Department of Signal Analysis, IHU LIRYC, Electrophysiology and Heart Modelling Institute, Bordeaux University, Bordeaux, France
| | - Gabriel Laurent
- Department of Cardiac Electrophysiology, Dijon University Hospital Center, Dijon, France
| | - Kristin Higgins
- Department of Radiation Oncology, Emory University, Atlanta, Georgia, USA
| | - Fabien Garnier
- Department of Cardiac Electrophysiology, Dijon University Hospital Center, Dijon, France
| | | | - Raphaël Martins
- Department of Signal Analysis, IHU LIRYC, Electrophysiology and Heart Modelling Institute, Bordeaux University, Bordeaux, France
- Department of Cardiac Electrophysiology, Rennes University Hospital Center, Rennes, France
| | - Antoine Da Costa
- Department of Cardiac Electrophysiology, Saint-Etienne University Hospital Center, Saint-Etienne, France
| | - Charles Guenancia
- Department of Radiation Oncology, Centre Eugene Marquis, Rennes, France
- PEC 2 EA 7460, University of Burgundy and Franche-Comté, Dijon, France
| |
Collapse
|
6
|
Huang DT, Gosev I, Wood KL, Vidula H, Stevenson W, Marchlinski F, Supple G, Zalawadiya SK, Weiss JP, Tung R, Tzou WS, Moss JD, Kancharla K, Chaudhry S, Patel PJ, Khan AM, Schuger C, Rozen G, Kiernan MS, Couper GS, Leacche M, Molina EJ, Shah AD, Lloyd M, Sroubek J, Soltesz E, Shivkumar K, White C, Tankut S, Johnson BA, McNitt S, Kutyifa V, Zareba W, Goldenberg I. Design and characteristics of the prophylactic intra-operative ventricular arrhythmia ablation in high-risk LVAD candidates (PIVATAL) trial. Ann Noninvasive Electrocardiol 2023; 28:e13073. [PMID: 37515396 PMCID: PMC10475893 DOI: 10.1111/anec.13073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/27/2023] [Revised: 04/25/2023] [Accepted: 06/27/2023] [Indexed: 07/30/2023] Open
Abstract
BACKGROUND The use of a Left Ventricular Assist Device (LVAD) in patients with advanced heart failure refractory to optimal medical management has progressed steadily over the past two decades. Data have demonstrated reduced LVAD efficacy, worse clinical outcome, and higher mortality for patients who experience significant ventricular tachyarrhythmia (VTA). We hypothesize that a novel prophylactic intra-operative VTA ablation protocol at the time of LVAD implantation may reduce the recurrent VTA and adverse events postimplant. METHODS We designed a prospective, multicenter, open-label, randomized-controlled clinical trial enrolling 100 patients who are LVAD candidates with a history of VTA in the previous 5 years. Enrolled patients will be randomized in a 1:1 fashion to intra-operative VTA ablation (n = 50) versus conventional medical management (n = 50) with LVAD implant. Arrhythmia outcomes data will be captured by an implantable cardioverter defibrillator (ICD) to monitor VTA events, with a uniform ICD programming protocol. Patients will be followed prospectively over a mean of 18 months (with a minimum of 9 months) after LVAD implantation to evaluate recurrent VTA, adverse events, and procedural outcomes. Secondary endpoints include right heart function/hemodynamics, healthcare utilization, and quality of life. CONCLUSION The primary aim of this first-ever randomized trial is to assess the efficacy of intra-operative ablation during LVAD surgery in reducing VTA recurrence and improving clinical outcomes for patients with a history of VTA.
Collapse
Affiliation(s)
- David T. Huang
- Division of CardiologyUniversity of Rochester Medical CenterRochesterNew YorkUSA
| | - Igor Gosev
- Division of Cardiothoracic SurgeryUniversity of Rochester Medical CenterRochesterNew YorkUSA
| | - Katherine L. Wood
- Division of Cardiothoracic SurgeryUniversity of Rochester Medical CenterRochesterNew YorkUSA
| | - Hima Vidula
- Division of CardiologyUniversity of Pennsylvania Medical CenterPhiladelphiaPennsylvaniaUSA
| | - William Stevenson
- Division of Cardiovascular MedicineVanderbilt University Medical CenterNashvilleTennesseeUSA
| | - Frank Marchlinski
- Division of CardiologyUniversity of Pennsylvania Medical CenterPhiladelphiaPennsylvaniaUSA
| | - Gregory Supple
- Division of CardiologyUniversity of Pennsylvania Medical CenterPhiladelphiaPennsylvaniaUSA
| | - Sandip K. Zalawadiya
- Division of Cardiovascular MedicineVanderbilt University Medical CenterNashvilleTennesseeUSA
| | - J. Peter Weiss
- The University of Arizona College of Medicine‐Phoenix, Banner University Medical CenterPhoenixArizonaUSA
| | - Roderick Tung
- The University of Arizona College of Medicine‐Phoenix, Banner University Medical CenterPhoenixArizonaUSA
| | - Wendy S. Tzou
- Division of CardiologyUniversity of Colorado Anschutz Medical CampusAuroraColoradoUSA
| | - Joshua D. Moss
- Division of CardiologyUniversity of California‐San FranciscoSan FranciscoCaliforniaUSA
| | - Krishna Kancharla
- Department of MedicineHeart and Vascular Institute, University of Pittsburgh Medical Center and School of MedicinePittsburghPennsylvaniaUSA
| | - Sunit‐Preet Chaudhry
- Division of CardiologyAscension St. Vincent Heart CenterIndianapolisIndianaUSA
- Ascension St. Vincent Cardiovascular Research InstituteIndianapolisIndianaUSA
| | - Parin J. Patel
- Division of CardiologyAscension St. Vincent Heart CenterIndianapolisIndianaUSA
- Ascension St. Vincent Cardiovascular Research InstituteIndianapolisIndianaUSA
| | - Arfaat M. Khan
- Henry Ford Heart and Vascular Institute, Henry Ford HospitalDetroitMichiganUSA
| | - Claudio Schuger
- Henry Ford Heart and Vascular Institute, Henry Ford HospitalDetroitMichiganUSA
| | - Guy Rozen
- Cardiovascular Center, Tufts Medical CenterBostonMassachusettsUSA
| | | | | | - Marzia Leacche
- Department of Cardiothoracic SurgerySpectrum HealthGrand RapidsMichiganUSA
| | - Ezequiel J. Molina
- Department of Cardiothoracic SurgeryPiedmont Heart InstituteAtlantaGeorgiaUSA
| | - Anand D. Shah
- Section of Cardiac ElectrophysiologyEmory University School of MedicineAtlantaGeorgiaUSA
| | - Michael Lloyd
- Section of Cardiac ElectrophysiologyEmory University School of MedicineAtlantaGeorgiaUSA
| | - Jakub Sroubek
- Heart Vascular and Thoracic Institute, Cleveland ClinicClevelandOhioUSA
| | - Edward Soltesz
- Department of Thoracic and Cardiovascular SurgeryCleveland ClinicClevelandOhioUSA
| | - Kalyanam Shivkumar
- UCLA Cardiac Arrhythmia Center, UCLA Health System, David Geffen School of Medicine at UCLALos AngelesCaliforniaUSA
| | - Casey White
- Division of CardiologyUniversity of Rochester Medical CenterRochesterNew YorkUSA
| | - Sinan Tankut
- Division of CardiologyUniversity of Rochester Medical CenterRochesterNew YorkUSA
| | - Brent A. Johnson
- Department of Biostatistics and Computational BiologyUniversity of RochesterRochesterNew YorkUSA
| | - Scott McNitt
- Clinical Cardiovascular Research CenterUniversity of Rochester Medical CenterRochesterNew YorkUSA
| | - Valentina Kutyifa
- Clinical Cardiovascular Research CenterUniversity of Rochester Medical CenterRochesterNew YorkUSA
| | - Wojciech Zareba
- Clinical Cardiovascular Research CenterUniversity of Rochester Medical CenterRochesterNew YorkUSA
| | - Ilan Goldenberg
- Clinical Cardiovascular Research CenterUniversity of Rochester Medical CenterRochesterNew YorkUSA
| |
Collapse
|
7
|
Vriz O, Mushtaq A, Shaik A, El-Shaer A, Feras K, Eltayeb A, Alsergnai H, Kholaif N, Al Hussein M, Albert-Brotons D, Simon AR, Tsai FW. Reciprocal interferences of the left ventricular assist device and the aortic valve competence. Front Cardiovasc Med 2023; 9:1094796. [PMID: 36698950 PMCID: PMC9870593 DOI: 10.3389/fcvm.2022.1094796] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2022] [Accepted: 12/22/2022] [Indexed: 01/12/2023] Open
Abstract
Patients suffering from end-stage heart failure tend to have high mortality rates. With growing numbers of patients progressing into severe heart failure, the shortage of available donors is a growing concern, with less than 10% of patients undergoing cardiac transplantation (CTx). Fortunately, the use of left ventricular assist devices (LVADs), a variant of mechanical circulatory support has been on the rise in recent years. The expansion of LVADs has led them to be incorporated into a variety of clinical settings, based on the goals of therapy for patients ailing from heart failure. However, with an increase in the use of LVADs, there are a host of complications that arise with it. One such complication is the development and progression of aortic regurgitation (AR) which is noted to adversely influence patient outcomes and compromise pump benefits leading to increased morbidity and mortality. The underlying mechanisms are likely multifactorial and involve the aortic root-aortic valve (AV) complex, as well as the LVAD device, patient, and other factors, all of them alter the physiological mechanics of the heart resulting in AV dysfunction. Thus, it is imperative to screen patients before LVAD implantation for AR, as moderate or greater AR requires a concurrent intervention at the time of LVADs implantation. No current strict guidelines were identified in the literature search on how to actively manage and limit the development and/or progression of AR, due to the limited information. However, some recommendations include medical management by targeting fluid overload and arterial blood pressure, along with adjusting the settings of the LVADs device itself. Surgical interventions are to be considered depending on patient factors, goals of care, and the underlying pathology. These interventions include the closure of the AV, replacement of the valve, and percutaneous approach via percutaneous occluding device or transcatheter aortic valve implantation. In the present review, we describe the interaction between AV and LVAD placement, in terms of patient management and prognosis. Also it is provided a comprehensive echocardiographic strategy for the precise assessment of AV regurgitation severity.
Collapse
Affiliation(s)
- Olga Vriz
- Heart Centre Department, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia,*Correspondence: Olga Vriz,
| | - Ali Mushtaq
- School of Medicine, Alfaisal University, Riyadh, Saudi Arabia
| | - Abdullah Shaik
- School of Medicine, Alfaisal University, Riyadh, Saudi Arabia
| | - Ahmed El-Shaer
- School of Medicine, Alfaisal University, Riyadh, Saudi Arabia
| | - Khalid Feras
- Heart Centre Department, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
| | - Abdalla Eltayeb
- Heart Centre Department, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
| | - Hani Alsergnai
- Heart Centre Department, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
| | - Naji Kholaif
- Heart Centre Department, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
| | - Mosaad Al Hussein
- Heart Centre Department, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
| | - Dimpna Albert-Brotons
- Heart Centre Department, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
| | - Andre Rudiger Simon
- Heart Centre Department, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
| | - Felix Wang Tsai
- Heart Centre Department, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
| |
Collapse
|
8
|
Abu Akel M, Shaul AA, Goldenberg GR, Barac YD, Ben-Avraham B, Gorfil D, Aravot D, Ben-Gal T. Combined mechanical circulatory support for ventricular fibrillation in left ventricular assist device patient. ESC Heart Fail 2022; 9:3593-3596. [PMID: 35715959 DOI: 10.1002/ehf2.13980] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2021] [Revised: 03/12/2022] [Accepted: 05/08/2022] [Indexed: 11/08/2022] Open
Abstract
Ventricular fibrillation, a life-threatening ventricular arrhythmia, may result in pulselessness, loss of consciousness and sudden cardiac death. In this case report, we describe our experience in managing a 54-year-old man with HeartMate3 left ventricular assist device (LVAD) as a bridge to transplantation due to dilated non-ischemic cardiomyopathy, presenting with incessant ventricular arrhythmia for 35 days despite multiple attempts to restore normal rhythm with external direct current cardioversion and anti-arrhythmic medications. The patient remained stable in ventricular arrhythmia with no progression to asystole, but hemodynamic collapse due to right heart failure occurred in the third week. Combined use of two mechanical circulatory support devices (LVAD with VA ECMO) was needed to achieve haemodynamic and metabolic stability, eventually leading to successful heart transplantation in the index admission. The patient was discharged home 2 weeks after transplantation in good clinical condition.
Collapse
Affiliation(s)
- Mahmood Abu Akel
- Heart Failure Unit, Department of Cardiology, Rabin Medical Center-Beilinson Hospital, Petah Tikva, Israel.,Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.,Department of Cardiovascular Medicine, Lady Davis Carmel Medical Center, Haifa, Israel.,Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
| | - Aviv A Shaul
- Heart Failure Unit, Department of Cardiology, Rabin Medical Center-Beilinson Hospital, Petah Tikva, Israel.,Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Gustavo R Goldenberg
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.,Cardiac Electrophysiology and Pacing Unit, Department of Cardiology, Rabin Medical Center-Beilinson Hospital, Petah Tikva, Israel
| | - Yaron D Barac
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.,Department of Cardiothoracic Surgery, Rabin Medical Center-Beilinson Hospital, Petah Tikva, Israel
| | - Binyamin Ben-Avraham
- Heart Failure Unit, Department of Cardiology, Rabin Medical Center-Beilinson Hospital, Petah Tikva, Israel.,Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Dan Gorfil
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.,Department of Cardiothoracic Surgery, Rabin Medical Center-Beilinson Hospital, Petah Tikva, Israel
| | - Dan Aravot
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.,Department of Cardiothoracic Surgery, Rabin Medical Center-Beilinson Hospital, Petah Tikva, Israel
| | - Tuvia Ben-Gal
- Heart Failure Unit, Department of Cardiology, Rabin Medical Center-Beilinson Hospital, Petah Tikva, Israel.,Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| |
Collapse
|
9
|
Gopinathannair R, Pothineni NVK, Trivedi JR, Roukoz H, Cowger J, Ahmed MM, Bhan A, K. Ravichandran A, Bhat G, Al Ahmad A, Natale A, Di Biase L, Slaughter MS, Lakkireddy D. Amiodarone Use and All-Cause Mortality in Patients With a Continuous-Flow Left Ventricular Assist Device. J Am Heart Assoc 2022; 11:e023762. [PMID: 35656998 PMCID: PMC9238747 DOI: 10.1161/jaha.121.023762] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background Atrial and ventricular arrhythmias are commonly encountered in patients with advanced heart failure, with amiodarone being the most commonly used antiarrhythmic drug in continuous‐flow left ventricular assist device (CF‐LVAD) recipients. The purpose of this study was to assess the impact of amiodarone use on long‐term all‐cause mortality in ptients with a CF‐LVAD. Methods and Results A retrospective multicenter study of CF‐LVAD was conducted at 5 centers including all CF‐LVAD implants from 2007 to 2015. Patients were stratified based on pre–CF‐LVAD implant amiodarone use. Additional use of amiodarone after CF‐LVAD implantation was also evaluated. Primary outcome was all‐cause mortality during long‐term follow‐up. Kaplan‐Meier curves were used to assess survival outcomes. Multivariable Cox regression was used to identify predictors of outcomes. Propensity matching was done to address baseline differences. A total of 480 patients with a CF‐LVAD (aged 58±13 years, 81% men) were included. Of these, 170 (35.4%) were on chronic amiodarone therapy at the time of CF‐LVAD implant, and 310 (64.6%) were not on amiodarone. Rate of all‐cause mortality over the follow‐up period was 32.9% in the amiodarone group compared with 29.6% in those not on amiodarone (P=0.008). Similar results were noted in the propensity‐matched group (log‐rank, P=0.04). On multivariable Cox regression analysis, amiodarone use at baseline was independently associated with all‐cause mortality (hazard ratio, 1.68 [95% CI, 1.1–2.5]; P=0.01). Conclusions Amiodarone use was associated with significantly increased rates of all‐cause mortality in CF‐LVAD recipients. Earlier interventions for arrhythmias to avoid long‐term amiodarone exposure may improve long‐term outcomes in CF‐LVAD recipients and needs further study.
Collapse
Affiliation(s)
| | | | - Jaimin R. Trivedi
- Department of Cardiothoracic SurgeryUniversity of LouisvilleLouisvilleKY
| | - Henri Roukoz
- Division of CardiologyUniversity of MinnesotaMinneapolisMN
| | | | | | - Adarsh Bhan
- Division of CardiologyAdvocate Christ Medical CenterOak LawnIL
| | | | - Geetha Bhat
- Division of CardiologyPennsylvania State UniversityHersheyPA
| | | | | | - Luigi Di Biase
- Division of CardiologyMontefiore Medical CenterNew YorkNY
| | - Mark S. Slaughter
- Department of Cardiothoracic SurgeryUniversity of LouisvilleLouisvilleKY
| | | |
Collapse
|
10
|
Shi J, Yu X, Liu Z. A review of new-onset ventricular arrhythmia after left ventricular assist device implantation. Cardiology 2022; 147:315-327. [PMID: 35483328 PMCID: PMC9393833 DOI: 10.1159/000524779] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/18/2022] [Accepted: 04/24/2022] [Indexed: 01/01/2023]
Abstract
INTRODUCTION Heart failure (HF) is a severe and terminal stage of various heart diseases. Left ventricular assist devices (LVADs) are relatively mature and have contributed to the treatment of end-stage HF. Ventricular arrhythmia (VA) is a common complication after LVAD implantation, including ventricular tachycardia and ventricular fibrillation, both of which may cause abnormal circulation in the body. METHODS A literature search was conducted in the PubMed database, "Ventricular Arrhythmia" OR "VA" OR "Arrhythmia" OR "Ventricular Tachycardia," OR "Ventricular Fibrillation" AND "LVAD" OR "Left Ventricular Assist Device" OR "Heart Assist Device" as either keywords or MeSH terms, the authors screened the titles and abstracts of the articles. Eventually, 12 original research articles were retrieved. RESULTS The 0.83 [95%CI: 0.77, 0.89] of patients were male. A whole of 53% [95%CI:0.25, 0.81] of VA patients had a history of atrial fibrillation and 61% [95%CI:0.52, 0.69] had a history of VA. 39% [95%CI:0.29, 0.49] of the participants had no prior history of VA and experienced new VA following CF-LVAD implantation. Following CF-LVAD implantation, 59% [95%CI:0.51, 0.67] of patients developed the early VA (VA ≤ 30 days). The 30-day mortality of patients was 4% [95%CI:0.01, 0.07]. And overall mortality was 28% [95%CI:0.15, 0.41] The reported incidence of VA after LVAD implantation is not identical in different medical centers and ranges from 20% to 60%. The mechanism of VA after LVAD implantation is summarized as primary cardiomyopathy-related, device mechanical stimulation, myocardial scarring, ventricular displacement, electrolyte regulation, and other processes. CONCLUSIONS A preoperative VA history is considered a predictor of VA following LVAD implantation in most studies. Multiple mechanisms and factors, such as prevention of "suction events", ablation, and ICD, should be considered for the prevention and treatment of postoperative VA in patients requiring long-term VAD treatment. This study provides a reference for the clinical application of LAVD and the prevention of postoperative VA after LVAD implantation. Future multicenter prospective studies with uniform patient follow-up are needed to screen for additional potential risk factors and predictors. These studies will help to define the incidence rate of VA after LAVD implantation. As a result, we provide guidance for the selection of preventive intervention.
Collapse
|
11
|
Kumai Y, Seguchi O, Mochizuki H, Kimura Y, Iwasaki K, Kuroda K, Nakajima S, Matsumoto Y, Watanabe T, Yanase M, Sata M, Fukushima S, Fujita T, Chikamori T, Kobayashi J, Fukushima N. Impact of sleep-disordered breathing on ventricular tachyarrhythmias after left ventricular assist device implantation. J Artif Organs 2022; 25:223-230. [PMID: 35022936 DOI: 10.1007/s10047-021-01307-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2021] [Accepted: 11/30/2021] [Indexed: 10/19/2022]
Abstract
Sleep-disordered breathing (SDB) is associated with an increased risk of adverse events in patients with heart failure (HF); however, its impact in patients implanted with a left ventricular assist device (LVAD) remains unclear. We aimed to investigate the prevalence of SDB in patients with LVAD and its impact on their clinical outcomes. Fifty consecutive patients with LVAD who underwent portable sleep monitoring between September 2017 and April 2018 were prospectively enrolled, and they were followed up for 170 ± 36 days. According to their respiratory disturbance indexes (RDIs), they were categorized into the SDB group (RDI ≥ 15, n = 12) and the non-SDB group (RDI < 15, n = 38). The incidence of adverse events during the follow-up period was investigated after enrollment. Multivariate logistic regression analysis revealed significant differences in SDB in LVAD-implanted patients in terms of the logarithmic transformation brain natriuretic peptide (BNP) values (p = 0.005). The optimal BNP cut-off value for SDB prediction in LVAD-implanted patients was 300 pg/mL (sensitivity: 58.3%, specificity: 94.7%). During follow-up, ventricular tachyarrhythmias (VTas) occurred significantly more frequently in the SDB group (4 [33%] vs. 2 [5%] patients, p = 0.02); Atrial tachyarrhythmia (ATa) also tended to occur more frequently in the SDB group (2 [25%] vs. 2 [2%] patients, p = 0.07). SBD was prevalent in 24% of the LVAD-implanted patients with advanced HF. Furthermore, SDB was significantly associated with high BNP levels and was also potentially associated with subsequent incidence of VTa in patients with LVAD.
Collapse
Affiliation(s)
- Yuto Kumai
- Department of Transplant Medicine, National Cerebral and Cardiovascular Center, 6-1 Kishibeshinmachi, Suita, Osaka, 564-8565, Japan
| | - Osamu Seguchi
- Department of Transplant Medicine, National Cerebral and Cardiovascular Center, 6-1 Kishibeshinmachi, Suita, Osaka, 564-8565, Japan.
| | - Hiroki Mochizuki
- Department of Transplant Medicine, National Cerebral and Cardiovascular Center, 6-1 Kishibeshinmachi, Suita, Osaka, 564-8565, Japan
| | - Yuki Kimura
- Department of Transplant Medicine, National Cerebral and Cardiovascular Center, 6-1 Kishibeshinmachi, Suita, Osaka, 564-8565, Japan
| | - Keiichiro Iwasaki
- Department of Transplant Medicine, National Cerebral and Cardiovascular Center, 6-1 Kishibeshinmachi, Suita, Osaka, 564-8565, Japan
| | - Kensuke Kuroda
- Department of Transplant Medicine, National Cerebral and Cardiovascular Center, 6-1 Kishibeshinmachi, Suita, Osaka, 564-8565, Japan
| | - Seiko Nakajima
- Department of Transplant Medicine, National Cerebral and Cardiovascular Center, 6-1 Kishibeshinmachi, Suita, Osaka, 564-8565, Japan
| | - Yorihiko Matsumoto
- Department of Pulmonology and Infection Control, National Cerebral and Cardiovascular Center, Osaka, Japan
| | - Takuya Watanabe
- Department of Transplant Medicine, National Cerebral and Cardiovascular Center, 6-1 Kishibeshinmachi, Suita, Osaka, 564-8565, Japan
| | - Masanobu Yanase
- Department of Transplant Medicine, National Cerebral and Cardiovascular Center, 6-1 Kishibeshinmachi, Suita, Osaka, 564-8565, Japan
| | - Makoto Sata
- Department of Pulmonology and Infection Control, National Cerebral and Cardiovascular Center, Osaka, Japan
| | - Satsuki Fukushima
- Department of Cardiovascular Surgery, National Cerebral and Cardiovascular Center, Osaka, Japan
| | - Tomoyuki Fujita
- Department of Cardiovascular Surgery, National Cerebral and Cardiovascular Center, Osaka, Japan
| | | | - Junjiro Kobayashi
- Department of Cardiovascular Surgery, National Cerebral and Cardiovascular Center, Osaka, Japan
| | - Norihide Fukushima
- Department of Transplant Medicine, National Cerebral and Cardiovascular Center, 6-1 Kishibeshinmachi, Suita, Osaka, 564-8565, Japan.
| |
Collapse
|
12
|
Robinson A, Parikh V, Jazayeri MA, Pierpoline M, Reddy YM, Emert M, Pimentel R, Dendi R, Berenbom L, Noheria A, Ramirez R, Sauer AJ, Shah Z, Abicht T, Haglund N, Sheldon SH. Impact of ultra-conservative ICD programming in patients with LVADs: Avoiding potentially unnecessary tachy-therapies. Pacing Clin Electrophysiol 2022; 45:204-211. [PMID: 34978089 DOI: 10.1111/pace.14438] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/27/2021] [Revised: 12/06/2021] [Accepted: 12/19/2021] [Indexed: 11/27/2022]
Abstract
BACKGROUND Patients with left ventricular assist devices (LVAD) often tolerate ventricular arrhythmias (VA). We aim to assess the frequency and outcomes of ICD therapies averted by ultraconservative ICD programming (UCP) in LVAD patients. METHODS This single center, retrospective cohort study included patients with LVADs and ICDs implanted from 2015 to 2019 that had UCP. The aim for UCP was to maximally delay VA treatments and maximize anti-tachycardia pacing (ATP) prior to ICD shocks. VA events were reviewed after UCP and evaluated under prior conservative programming to assess for potentially averted events (that would have resulted in either ATP or defibrillation with prior programming). RESULTS Fifty patients were included in the study with follow-up of median 16 ± 10.2 months after UCP. The median time from LVAD implantation to reprogramming was 7 days (IQR 5-9 days). Fourteen patients (28%) had potentially averted VA events that would have been treated with their prior ICD programming (82 total events, median two events per patient, IQR 1-10 events). Treated VA events occurred in 15 patients (30%). Eleven of the 14 patients with potentially averted VAs had treated events as well. Only one patient reported definitive symptoms of self-limited "dizziness" during a potentially averted event that did not result in hospitalization. No patients died of complications from or needed emergent care/hospitalization due a potentially averted VA. CONCLUSIONS UCP in LVAD patients likely prevented unnecessary VA treatments in many patients with minimal reported symptoms during these potentially averted events. Prospective studies are necessary to confirm these findings.
Collapse
Affiliation(s)
- Alexander Robinson
- Department of Cardiovascular Medicine, The University of Kansas Health System, Kansas City, Kansas, USA
| | - Valay Parikh
- Department of Cardiovascular Medicine, The University of Kansas Health System, Kansas City, Kansas, USA
| | - Mohammad-Ali Jazayeri
- Department of Cardiovascular Medicine, The University of Kansas Health System, Kansas City, Kansas, USA
| | - Michael Pierpoline
- Department of Cardiovascular Medicine, The University of Kansas Health System, Kansas City, Kansas, USA
| | - Y Madhu Reddy
- Department of Cardiovascular Medicine, The University of Kansas Health System, Kansas City, Kansas, USA
| | - Martin Emert
- Department of Cardiovascular Medicine, The University of Kansas Health System, Kansas City, Kansas, USA
| | - Rhea Pimentel
- Department of Cardiovascular Medicine, The University of Kansas Health System, Kansas City, Kansas, USA
| | - Raghuveer Dendi
- Department of Cardiovascular Medicine, The University of Kansas Health System, Kansas City, Kansas, USA
| | - Loren Berenbom
- Department of Cardiovascular Medicine, The University of Kansas Health System, Kansas City, Kansas, USA
| | - Amit Noheria
- Department of Cardiovascular Medicine, The University of Kansas Health System, Kansas City, Kansas, USA
| | - Rigoberto Ramirez
- Department of Cardiovascular Medicine, The University of Kansas Health System, Kansas City, Kansas, USA
| | - Andrew J Sauer
- Department of Cardiovascular Medicine, The University of Kansas Health System, Kansas City, Kansas, USA
| | - Zubair Shah
- Department of Cardiovascular Medicine, The University of Kansas Health System, Kansas City, Kansas, USA
| | - Travis Abicht
- Department of Cardiovascular Surgery, The University of Kansas Health System, Kansas City, Kansas, USA
| | - Nicholas Haglund
- Department of Cardiovascular Medicine, The University of Kansas Health System, Kansas City, Kansas, USA
| | - Seth H Sheldon
- Department of Cardiovascular Medicine, The University of Kansas Health System, Kansas City, Kansas, USA
| |
Collapse
|
13
|
Pathophysiology of heart failure and an overview of therapies. Cardiovasc Pathol 2022. [DOI: 10.1016/b978-0-12-822224-9.00025-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
14
|
Sisti N, Santoro A, Carreras G, Valente S, Donzelli S, Mandoli GE, Sciaccaluga C, Cameli M. Ablation therapy for ventricular arrhythmias in patients with LVAD: Multiple faces of an electrophysiological challenge. J Arrhythm 2021; 37:535-543. [PMID: 34141004 PMCID: PMC8207352 DOI: 10.1002/joa3.12542] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2020] [Revised: 03/12/2021] [Accepted: 04/04/2021] [Indexed: 12/15/2022] Open
Abstract
Left ventricular assist device implantation is a recognized treatment option for patients with advanced heart failure refractory to medical therapy and can be used both as bridge to transplantation and as destination therapy. The risk of ventricular arrhythmias is common after left ventricular assist device implantation and is influenced by pre-, peri and post-operative determinants. The management of ventricular arrhythmias can be a challenge when they become refractory to medication or to device therapy and their impact on prognosis can be detrimental despite the mechanical support. In this setting, catheter ablation is being increasingly recognized as a feasible option for patients in which standard therapeutic strategies fail, but also with preventive purpose. Catheter ablation is being increasingly considered for the management of ventricular arrhythmias in patients with left ventricular assist device despite complex clinical and technical peculiarities due to the characteristics of the mechanical support. Much conflicting data exist regarding the predictors of success of the procedure and the rate of recurrence. In this review we discuss the latest evidences regarding catheter ablation of ventricular arrhythmias in this subset of patients, focusing on clinical characteristics, arrhythmia etiology, technical aspects and postprocedural features which must be considered by the electrophysiologist.
Collapse
Affiliation(s)
- Nicolò Sisti
- Department of Cardiovascular DiseasesUniversity of SienaSienaItaly
| | - Amato Santoro
- Department of Cardiovascular DiseasesUniversity of SienaSienaItaly
| | | | - Serafina Valente
- Department of Cardiovascular DiseasesUniversity of SienaSienaItaly
| | | | | | | | - Matteo Cameli
- Department of Cardiovascular DiseasesUniversity of SienaSienaItaly
| |
Collapse
|
15
|
Li A, Atteya G, Vullaganti S, Mitra R. Surface mapping demonstrates compatibility of implantable loop monitor with a continuous-flow left ventricular assist device. ESC Heart Fail 2021; 8:3392-3396. [PMID: 34042310 PMCID: PMC8318441 DOI: 10.1002/ehf2.13343] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2021] [Revised: 03/02/2021] [Accepted: 03/24/2021] [Indexed: 12/13/2022] Open
Abstract
Syncope in patients with continuous‐flow left ventricular assist device may be associated with arrhythmia and difficult to determine without an implantable cardioverter defibrillator. We present a patient with continuous‐flow left ventricular assist device, no implantable cardioverter defibrillator, and recurrent syncope. An implantable loop recorder was successfully implanted with surface mapping without noise interference.
Collapse
Affiliation(s)
- Angela Li
- Department of Cardiology, Sandra Atlas Bass Heart Hospital, North Shore University Hospital, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, 300 Community Drive, 1 Cohen, Manhasset, NY, 11030, USA
| | - Gourg Atteya
- Department of Cardiology, Sandra Atlas Bass Heart Hospital, North Shore University Hospital, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, 300 Community Drive, 1 Cohen, Manhasset, NY, 11030, USA
| | - Sirish Vullaganti
- Department of Cardiology, Sandra Atlas Bass Heart Hospital, North Shore University Hospital, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, 300 Community Drive, 1 Cohen, Manhasset, NY, 11030, USA
| | - Ramanak Mitra
- Department of Cardiology, Sandra Atlas Bass Heart Hospital, North Shore University Hospital, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, 300 Community Drive, 1 Cohen, Manhasset, NY, 11030, USA
| |
Collapse
|
16
|
Shehadeh M, Brar V, Costello J, Hadadi C, O'Donoghue S, Worley S. Ineffective implantable cardioverter-defibrillator shocks among patients on continuous left ventricular assist device support: Clinical characteristics and management. Heart Rhythm O2 2020; 1:336-340. [PMID: 34113891 PMCID: PMC8183971 DOI: 10.1016/j.hroo.2020.11.001] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
Background Placement of a left ventricular assist device (LVAD) has been described to compromise implantable cardioverter-defibrillator (ICD) defibrillation threshold (DFT). Elevated DFT will have negative consequences and increases the risk of ineffective ICD shocks, morbidity, and mortality. DFT testing is not routinely performed in clinical practice, despite this fact. Objective We describe the clinical characteristics of 7 LVAD patients who presented with multiple ineffective ICD shocks, along with the management strategy in such patients. Methods Seven patients (5 male, mean age 52.2 ± 9 years, 85.7% nonischemic cardiomyopathy) with an ICD in situ who progressed to NYHA class IV, ACC/AHA stage D chronic systolic congestive heart failure who underwent successful LVAD implantation presented to our institution in the setting of ventricular tachyarrhythmia and ineffective ICD shocks. Six patients underwent implantation of azygos and subclavian coils with subsequent DFT testing. The remaining patient was made comfort care. Results Five patients had successful DFT testing with azygos (n = 4) and subclavian (n = 1) defibrillation coil implantation. One patient had unsuccessful DFT testing despite evaluation of multiple shock vectors. There were no major or minor vascular complications in any of the cases. There were no procedural-related deaths. Conclusion This case series highlights the need for a systematic approach to management of ICDs and DFT testing in LVAD patients. The addition of new shock vectors with azygos and subclavian coil implantation may reduce DFT, shock burden, morbidity, and mortality.
Collapse
Affiliation(s)
| | | | | | - Cyrus Hadadi
- Medstar Washington Hospital Center, Washington, DC
| | | | - Seth Worley
- Medstar Washington Hospital Center, Washington, DC
| |
Collapse
|
17
|
Abstract
PURPOSE OF REVIEW Left ventricular assist devices (LVADs) have extended the life expectancy of patients with heart failure. The hemodynamic support afforded by LVADs in this population has also resulted in patients having prolonged ventricular arrhythmias. The purpose of this article is to review the mechanisms of ventricular arrhythmias in LVADs and the available management strategies. RECENT FINDINGS Recent evidence suggests that prolonged ventricular arrhythmias may result in increased mortality in patients with LVADs. SUMMARY Successful management of ventricular arrhythmias in patients with LVAD requires interdisciplinary collaboration between electrophysiology and heart failure specialists. Medical management, including changes to LVAD changes, heart failure medication management, and antiarrhythmics constitute the initial treatment for ventricular arrhythmias. Surgical or endocardial ablation are reasonable options if VAs are refractory.
Collapse
|
18
|
Gordon JS, Maynes EJ, Choi JH, Wood CT, Weber MP, Morris RJ, Massey HT, Tchantchaleishvili V. Ventricular arrhythmias following continuous-flow left ventricular assist device implantation: A systematic review. Artif Organs 2020; 44:E313-E325. [PMID: 32043582 DOI: 10.1111/aor.13665] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2019] [Revised: 02/05/2020] [Accepted: 02/07/2020] [Indexed: 12/16/2022]
Abstract
Ventricular arrhythmias (VA) are not uncommon after continuous-flow left ventricular assist device (CF-LVAD) implantation. In this systematic review, we sought to identify the patterns of VA that occurred following CF-LVAD implantation and evaluate their outcomes. An electronic search was performed to identify all articles reporting the development of VA following CF-LVAD implantation. VA was defined as any episode of ventricular fibrillation (VF) or sustained (>30 seconds) ventricular tachycardia (VT). Eleven studies were pooled for the analysis that included 393 CF-LVAD patients with VA. The mean patient age was 57 years [95%CI: 54; 61] and 82% [95%CI: 73; 88] were male. Overall, 37% [95%CI: 19; 60] of patients experienced a new onset VA after CF-LVAD implantation, while 60% [95%CI: 51; 69] of patients had a prior history of VA. Overall, 88% of patients [95%CI: 78; 94] were supported on HeartMate II CF-LVAD, 6% [95%CI: 3; 14] on HeartWare HVAD, and 6% [95%CI: 2; 13] on other CF-LVADs. VA was symptomatic in 47% [95%CI: 28; 68] of patients and in 50% [95%CI: 37; 52], early VA (<30 days from CF-LVAD) was observed. The 30-day mortality rate was 7% [95%CI: 5; 11]. Mean follow-up was 22.9 months [95%CI: 4.8; 40.8], during which 27% [95%CI: 17; 39] of patients underwent heart transplantation. In conclusion, approximately a third of patients had new VA following CF-LVAD placement. VA in CF-LVAD patients is often symptomatic, necessitates treatment, and carries a worse prognosis.
Collapse
Affiliation(s)
- Jonathan S Gordon
- Division of Cardiac Surgery, Thomas Jefferson University Hospital, Philadelphia, PA, USA
| | - Elizabeth J Maynes
- Division of Cardiac Surgery, Thomas Jefferson University Hospital, Philadelphia, PA, USA
| | - Jae Hwan Choi
- Division of Cardiac Surgery, Thomas Jefferson University Hospital, Philadelphia, PA, USA
| | - Chelsey T Wood
- Division of Cardiac Surgery, Thomas Jefferson University Hospital, Philadelphia, PA, USA
| | - Matthew P Weber
- Division of Cardiac Surgery, Thomas Jefferson University Hospital, Philadelphia, PA, USA
| | - Rohinton J Morris
- Division of Cardiac Surgery, Thomas Jefferson University Hospital, Philadelphia, PA, USA
| | - H Todd Massey
- Division of Cardiac Surgery, Thomas Jefferson University Hospital, Philadelphia, PA, USA
| | | |
Collapse
|
19
|
Orozco-Hernandez EJ, Argueta-Sosa EE, Joly JM, Pamboukian SV, Tallaj JA, Hoopes CW. Cryoablation during left ventricular assist device implantation: A case report. JTCVS Tech 2020; 1:55-57. [PMID: 34317713 PMCID: PMC8288615 DOI: 10.1016/j.xjtc.2020.01.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2019] [Revised: 11/25/2019] [Accepted: 01/03/2020] [Indexed: 10/25/2022] Open
|
20
|
Ventricular arrhythmias in patients with biventricular assist devices. J Interv Card Electrophysiol 2019; 58:243-252. [PMID: 31838665 PMCID: PMC7293581 DOI: 10.1007/s10840-019-00682-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/05/2019] [Accepted: 12/02/2019] [Indexed: 10/25/2022]
Abstract
PURPOSE Ventricular arrhythmias (VAs) are common in patients after left ventricular assist device (LVAD) implant and are associated with worse outcomes. However, the prevalence and impact of VA in patients with durable biventricular assist device (BIVAD) is unknown. We performed a retrospective cohort study of patients with BIVADs to evaluate the prevalence of VA and their clinical outcomes. METHODS Consecutive patients who received a BIVAD between June 2014 and July 2017 at our medical center were included. The prevalence of VA, defined as sustained ventricular tachycardia or fibrillation requiring defibrillation or ICD therapy, was compared between BIVAD patients and a propensity-matched population of patients with LVAD from our center. The occurrence of adverse clinical events was compared between BIVAD patients with and without VA. RESULTS Of the 13 patients with BIVADs, 6 patients (46%) experienced clinically significant VA, similar to a propensity-matched LVAD population (38%, p = 1.00). There were no differences in baseline characteristics between the two cohorts, except patients in the non-VA group who had worse hemodynamics (mitral regurgitation and right-sided indices), had less history of VA, and were younger. BIVAD patients with VA had a higher incidence of major bleeding (MR 3.05 (1.07-8.66), p = 0.036) and worse composite outcomes (log-rank test, p = 0.046). The presence of VA was associated with worse outcomes in both LVAD and BIVAD groups. CONCLUSIONS Ventricular arrhythmias are common in patients with BIVADs and are associated with worse outcomes. Future work should assess whether therapies such as ablation improve the outcome of BIVAD patients with VA.
Collapse
|
21
|
Ahmed A, Amin M, Boilson BA, Killu AM, Madhavan M. Ventricular Arrhythmias in Patients With Left Ventricular Assist Device (LVAD). CURRENT TREATMENT OPTIONS IN CARDIOVASCULAR MEDICINE 2019; 21:75. [PMID: 31773322 DOI: 10.1007/s11936-019-0783-7] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
PURPOSE OF REVIEW Left ventricular assist device (LVAD) implantation is a well-known treatment option for patients with advanced heart failure refractory to medical therapy and is recognized both as bridge to transplant and a destination therapy. The risk of ventricular arrhythmias (VAs) is common after LVAD implantation. We review the pathophysiology and recent advances in the management of VA in LVAD patients. RECENT FINDINGS VAs are most likely to occur in the early post-operative periods after LVAD implantation and a prior history of VA is the most important risk factor. Post-LVAD VAs are usually well tolerated with less morbidity and decreased risk of sudden cardiac death. However, risk of right heart failure in the setting of persistent VAs is being increasingly recognized. The mechanisms of post-LVAD VAs may vary depending on the time from LVAD implantation. Electrical remodeling may play an important role in the immediate post-implant phase. Preexisting myocardial scar and to a lesser extent mechanical irritation from the LVAD cannula are important in the later phases. Most LVAD patients have a previously placed implantable cardioverter-defibrillator (ICD). The benefit of implanting a new ICD in LVAD patients is unknown and should be individualized. For ICD programming, a conservative strategy with higher detection zones and prolonged time to detection is usually recommended aiming to minimize ICD shocks. More aggressive programming is appropriate if the VA results in hemodynamic instability. Antiarrhythmic drugs including amiodarone, mexiletine, and beta blockers are usually the first-line therapy for VAs. Catheter ablation has been shown to be safe and effective in LVAD recipients with recurrent VAs not responsive to antiarrhythmic drugs. LVAD-related VA is most frequently reentrant secondary to myocardial scar and usually well tolerated. Management options include antiarrhythmic drugs and catheter ablation.
Collapse
Affiliation(s)
- Azza Ahmed
- Department of Hospital Medicine, Mayo Clinic Health System, Eau Claire, WI, USA
| | - Mustapha Amin
- Department of Cardiovascular Diseases, Mayo Clinic, 200 First St SW, Rochester, MN, 55905, USA
| | - Barry A Boilson
- Department of Cardiovascular Diseases, Mayo Clinic, 200 First St SW, Rochester, MN, 55905, USA
| | - Ammar M Killu
- Department of Cardiovascular Diseases, Mayo Clinic, 200 First St SW, Rochester, MN, 55905, USA
| | - Malini Madhavan
- Department of Cardiovascular Diseases, Mayo Clinic, 200 First St SW, Rochester, MN, 55905, USA.
| |
Collapse
|
22
|
Atrial Fibrillation Is Associated with Recurrent Ventricular Arrhythmias After LVAD Implant: Incidence and Impact in a Consecutive Series. J Cardiovasc Transl Res 2019; 13:199-203. [PMID: 31696404 DOI: 10.1007/s12265-019-09914-0] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/28/2019] [Revised: 08/22/2019] [Accepted: 09/09/2019] [Indexed: 10/25/2022]
Abstract
This study examined left-ventricular assist device (LVAD) patients with pre-LVAD ventricular arrhythmias (VAs) to determine the rate of recurrent post-LVAD VAs and the impact of pre-LVAD atrial fibrillation (AF) on recurrent post-LVAD VAs. Medical records of 195 consecutive LVAD patients were reviewed. Descriptive statistics were generated and Cox proportional hazard models were used to assess the association of clinical variables with the time to recurrent VA. Forty-seven percent of 195 CHF patients who received LVAD-manifested significant VAs prior to LVAD implant (82% Heartmate II, 14% HVAD, 4% other; median follow-up = 17 months), 41% of whom manifested recurrent post-LVAD VAs. Pre-LVAD AF was associated with recurrent VAs (hazard ratio = 3.73; 95% CI 1.33, 10.48; p = 0.012). Recurrent VAs were associated with increased mortality (hazard ratio = 3.06; 95% CI 1.17, 7.98; p = 0.023). A history of AF is prevalent in over half of LVAD patients with recurrent VAs and is associated with time to recurrence of VA.
Collapse
|
23
|
Alvarez CK, Cronin E, Baker WL, Kluger J. Heart failure as a substrate and trigger for ventricular tachycardia. J Interv Card Electrophysiol 2019; 56:229-247. [PMID: 31598875 DOI: 10.1007/s10840-019-00623-x] [Citation(s) in RCA: 26] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/14/2019] [Accepted: 09/06/2019] [Indexed: 02/06/2023]
Abstract
Heart failure (HF) is a major cause of morbidity and mortality with more than 5.1 million individuals affected in the USA. Ventricular tachyarrhythmias (VAs) including ventricular tachycardia and ventricular fibrillation are common in patients with heart failure. The pathophysiology of these mechanisms as well as the contribution of heart failure to the genesis of these arrhythmias is complex and multifaceted. Myocardial hypertrophy and stretch with increased preload and afterload lead to shortening of the action potential at early repolarization and lengthening of the action potential at final repolarization which can result in re-entrant ventricular tachycardia. Myocardial fibrosis and scar can create the substrate for re-entrant ventricular tachycardia. Altered calcium handling in the failing heart can lead to the development of proarrhythmic early and delayed after depolarizations. Various medications used in the treatment of HF such as loop diuretics and angiotensin converting enzyme inhibitors have not demonstrated a reduction in sudden cardiac death (SCD); however, beta-blockers (BB) are effective in reducing mortality and SCD. Amongst patients who have HF with reduced ejection fraction, the angiotensin receptor-neprilysin inhibitor (sacubitril/valsartan) has been shown to reduce cardiovascular mortality, specifically by reducing SCD, as well as death due to worsening HF. Implantable cardioverter-defibrillator (ICD) implantation in HF patients reduces the risk of SCD; however, subsequent mortality is increased in those who receive ICD shocks. Prophylactic ICD implantation reduces death from arrhythmia but does not reduce overall mortality during the acute post-myocardial infarction (MI) period (less than 40 days), for those with reduced ejection fraction and impaired autonomic dysfunction. Furthermore, although death from arrhythmias is reduced, this is offset by an increase in the mortality from non-arrhythmic causes. This article provides a review of the aforementioned mechanisms of arrhythmogenesis in heart failure; the role and impact of HF therapy such as cardiac resynchronization therapy (CRT), including the role, if any, of CRT-P and CRT-D in preventing VAs; the utility of both non-invasive parameters as well as multiple implant-based parameters for telemonitoring in HF; and the effect of left ventricular assist device implantation on VAs.
Collapse
Affiliation(s)
- Chikezie K Alvarez
- Montefiore Medical Center, Albert Einstein College of Medicine, 111 East 210th Street, Bronx, NY, 10467, USA.
| | - Edmond Cronin
- University of Connecticut School of Medicine, Farmington, CT, USA
| | - William L Baker
- University of Connecticut School of Pharmacy, Storrs, CT, USA
| | - Jeffrey Kluger
- Hartford Healthcare Heart and Vascular Institute, Hartford Hospital, Hartford, CT, USA
| |
Collapse
|
24
|
Devabhaktuni SR, Shirazi JT, Miller JM. Mapping and Ablation of Ventricle Arrhythmia in Patients with Left Ventricular Assist Devices. Card Electrophysiol Clin 2019; 11:689-697. [PMID: 31706475 DOI: 10.1016/j.ccep.2019.07.001] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
Ventricular arrhythmias (VA) constitute well-known problems in patients with left ventricular assist devices (LVADs), with incidence ranging from 18% to as high as 52%. Catheter ablation has become a common therapeutic intervention to treat drug-refractory VA, particularly with the increase and more widespread use of durable LVADs to bridge patients to transplantation or as destination therapy. In this article, we focus on etiology, mechanisms, periprocedural management, and mapping and ablation techniques in patients with LVADs and VA.
Collapse
|
25
|
Kumar A, Tandon V, O'Sullivan DM, Cronin E, Gluck J, Kluger J. ICD shocks in LVAD patients are not associated with increased subsequent mortality risk. J Interv Card Electrophysiol 2019; 56:341-348. [PMID: 31506872 DOI: 10.1007/s10840-019-00619-7] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/31/2019] [Accepted: 08/27/2019] [Indexed: 11/30/2022]
Abstract
BACKGROUND Implantable cardioverter-defibrillator (ICD) shocks are associated with increased mortality risk in heart failure patients. Whether ICD shocks are associated with mortality in continuous flow LVAD (CF-LVAD) patients is unknown. We studied the relationship of ICD shocks and ventricular arrhythmias (VAs) to morbidity and mortality in CF-LVAD-supported patients in our institution. METHODS Single-center, retrospective study of prospectively collected ICD and LVAD databases. We analyzed data on VA which received ICD therapy in patients who underwent CF-LVAD implantation at Hartford Hospital between 2008 and 2018. RESULTS A total of 157 patients were studied. During a median follow-up of 10 months (interquartile range 5-20 months), 48 patients (30.6%) experienced post-LVAD sustained VA. Thirty patients (19.1%) had appropriate shocks for VA and 5 patients (3.1%) had inappropriate shocks. Shocks for any arrhythmia were not associated with an increased risk of death (OR 0.836, 95% CI 0.224-3.115, p = 0.789). Neither post-LVAD VA nor the rate of VA was associated with an increased mortality risk (OR 0.662 [0.329-1.334], p = 0.248; OR 1.001 [0.989-1.014], p = 0.817, respectively). Cox multivariate regression analysis revealed pre-LVAD VA as a significant predictor of VA post LVAD implantation (OR 3.284 [1.584-6.808], p = 0.001). Symptoms with VA occurred in 22 (45.8%) patients, ranging from palpitations to near syncope/syncope. None of the variables including the rate of VA was associated with death or symptoms. CONCLUSIONS VAs are common in CF-LVAD patients and occur with higher frequency in those with pre-LVAD VA and frequently cause symptoms. Neither VA nor ICD shocks are associated with mortality risk.
Collapse
Affiliation(s)
- Aswini Kumar
- Division of Cardiology, Hartford Hospital, Hartford, CT, USA. .,Department of Medicine, University of Connecticut, Farmington, CT, USA.
| | - Varun Tandon
- Department of Medicine, University of Connecticut, Farmington, CT, USA
| | - David M O'Sullivan
- Department of Research Administration, Hartford HealthCare, Hartford, CT, USA
| | - Edmond Cronin
- Division of Cardiology, Hartford Hospital, Hartford, CT, USA.,University of Connecticut School of Medicine, Farmington, CT, USA
| | - Jason Gluck
- Division of Cardiology, Hartford Hospital, Hartford, CT, USA.,University of Connecticut School of Medicine, Farmington, CT, USA
| | - Jeffrey Kluger
- Division of Cardiology, Hartford Hospital, Hartford, CT, USA.,University of Connecticut School of Medicine, Farmington, CT, USA
| |
Collapse
|
26
|
See Hoe LE, Bartnikowski N, Wells MA, Suen JY, Fraser JF. Hurdles to Cardioprotection in the Critically Ill. Int J Mol Sci 2019; 20:E3823. [PMID: 31387264 PMCID: PMC6695809 DOI: 10.3390/ijms20153823] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2019] [Revised: 07/26/2019] [Accepted: 08/03/2019] [Indexed: 02/07/2023] Open
Abstract
Cardiovascular disease is the largest contributor to worldwide mortality, and the deleterious impact of heart failure (HF) is projected to grow exponentially in the future. As heart transplantation (HTx) is the only effective treatment for end-stage HF, development of mechanical circulatory support (MCS) technology has unveiled additional therapeutic options for refractory cardiac disease. Unfortunately, despite both MCS and HTx being quintessential treatments for significant cardiac impairment, associated morbidity and mortality remain high. MCS technology continues to evolve, but is associated with numerous disturbances to cardiac function (e.g., oxidative damage, arrhythmias). Following MCS intervention, HTx is frequently the destination option for survival of critically ill cardiac patients. While effective, donor hearts are scarce, thus limiting HTx to few qualifying patients, and HTx remains correlated with substantial post-HTx complications. While MCS and HTx are vital to survival of critically ill cardiac patients, cardioprotective strategies to improve outcomes from these treatments are highly desirable. Accordingly, this review summarizes the current status of MCS and HTx in the clinic, and the associated cardiac complications inherent to these treatments. Furthermore, we detail current research being undertaken to improve cardiac outcomes following MCS/HTx, and important considerations for reducing the significant morbidity and mortality associated with these necessary treatment strategies.
Collapse
Affiliation(s)
- Louise E See Hoe
- Critical Care Research Group, The Prince Charles Hospital, Chermside 4032, Australia.
- Faculty of Medicine, University of Queensland, Chermside 4032, Australia.
| | - Nicole Bartnikowski
- Critical Care Research Group, The Prince Charles Hospital, Chermside 4032, Australia
- Science and Engineering Faculty, Queensland University of Technology, Chermside 4032, Australia
| | - Matthew A Wells
- Critical Care Research Group, The Prince Charles Hospital, Chermside 4032, Australia
- School of Medical Science, Griffith University, Southport 4222, Australia
| | - Jacky Y Suen
- Critical Care Research Group, The Prince Charles Hospital, Chermside 4032, Australia
- Faculty of Medicine, University of Queensland, Chermside 4032, Australia
| | - John F Fraser
- Critical Care Research Group, The Prince Charles Hospital, Chermside 4032, Australia
- Faculty of Medicine, University of Queensland, Chermside 4032, Australia
| |
Collapse
|
27
|
Almukhanova AB, Pivtsova AM, Zelenskaya YA. [Ventricular Fibrillation in a Patient with Implanted Left Ventricular Assist Device Heart Mate II]. KARDIOLOGIYA 2019; 59:95-96. [PMID: 31322095 DOI: 10.18087/cardio.2019.7.n340] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/10/2018] [Revised: 02/01/2019] [Accepted: 02/01/2019] [Indexed: 11/18/2022]
Abstract
In this article we present a clinical case of a 46-year-old man, who developed ventricular fibrillation at the background of implanted left ventricular assist device (LVAD) Heart Mate II because of dilated cardiomyopathy with biventricular chronic heart failure. Ventricular fibrillation required electrical and medical defibrillation with further treatment in the intensive care unit.
Collapse
Affiliation(s)
- A B Almukhanova
- Kazakh National Medical University named after S. D. Asfendiyarov
| | - A M Pivtsova
- Kazakh National Medical University named after S. D. Asfendiyarov
| | - Y A Zelenskaya
- Kazakh National Medical University named after S. D. Asfendiyarov
| |
Collapse
|
28
|
Yousefzai R, Brambatti M, Tran HA, Pedersen R, Braun OÖ, Baykaner T, Ghashghaei R, Sulemanjee NZ, Cheema OM, Rappelt M, Baeza C, Alkhayyat A, Shi Y, Pretorius V, Greenberg B, Adler E, Thohan V. Benefits of Neurohormonal Therapy in Patients With Continuous-Flow Left Ventricular Assist Devices. ASAIO J 2019; 66:409-414. [PMID: 31192845 DOI: 10.1097/mat.0000000000001022] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023] Open
Abstract
Left ventricular assist devices (LVADs) have dramatically improved short-term outcomes among patients with advanced heart failure. While neurohormonal blockade (NHB) is the cornerstone of treatment for patients with heart failure with reduced ejection fraction, its effect after LVAD placement has not been established. We reviewed medical records of 307 patients who underwent primary LVAD implantation from January 2006 to September 2015 at two institutions in the United States. Patients were followed for at least 2 years post-LVAD implantation or until explantation, heart transplantation, or death. Cox regression analysis stratifying on center was used to assess associations with mortality. Neurohormonal blockade use was treated as a time-dependent predictor. Stepwise selection indicated treatment with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (ACEIs/ARBs) (hazard ratio [HR] = 0.53 [0.30-0.95], p = 0.03), age at the time of implantation (HR = 1.28 [1.05-1.56] per decade, p = 0.02), length of stay postimplantation (HR = 1.16 [1.11-1.21] per week, p < 0.01) and INTERMACS profile of 1 or 2 (HR = 1.86 [1.17-2.97], p < 0.01) were independent predictors of mortality. In this large, retrospective study, treatment with ACEIs or ARBs was an independent factor associated with decreased mortality post-LVAD placement.
Collapse
Affiliation(s)
- Rayan Yousefzai
- From the Lifespan Cardiovascular Institute, Rhode Island Hospital, Brown University, Providence, Rhode Island.,Sulpizio Cardiovascular Center, University of California San Diego Health, La Jolla, California
| | - Michela Brambatti
- Sulpizio Cardiovascular Center, University of California San Diego Health, La Jolla, California
| | - Hao A Tran
- Sulpizio Cardiovascular Center, University of California San Diego Health, La Jolla, California
| | - Rachel Pedersen
- Aurora Cardiovascular Services, Aurora Sinai/Aurora St. Luke's Medical Centers, Milwaukee, Wisconsin
| | - Oscar Ö Braun
- Sulpizio Cardiovascular Center, University of California San Diego Health, La Jolla, California
| | - Tina Baykaner
- Sulpizio Cardiovascular Center, University of California San Diego Health, La Jolla, California
| | - Roxana Ghashghaei
- Sulpizio Cardiovascular Center, University of California San Diego Health, La Jolla, California
| | - Nasir Z Sulemanjee
- Aurora Cardiovascular Services, Aurora Sinai/Aurora St. Luke's Medical Centers, Milwaukee, Wisconsin
| | - Omar M Cheema
- Aurora Cardiovascular Services, Aurora Sinai/Aurora St. Luke's Medical Centers, Milwaukee, Wisconsin
| | - Matthew Rappelt
- Center for Integrative Research on Cardiovascular Aging (CIRCA), Aurora Research Institute, Aurora Health Care, Milwaukee, Wisconsin. Dr. Shi is now with the National Institutes of Health, Rockville, Maryland
| | - Carmela Baeza
- Sulpizio Cardiovascular Center, University of California San Diego Health, La Jolla, California
| | - Abdulaziz Alkhayyat
- Sulpizio Cardiovascular Center, University of California San Diego Health, La Jolla, California
| | - Yang Shi
- Center for Integrative Research on Cardiovascular Aging (CIRCA), Aurora Research Institute, Aurora Health Care, Milwaukee, Wisconsin. Dr. Shi is now with the National Institutes of Health, Rockville, Maryland
| | - Victor Pretorius
- Sulpizio Cardiovascular Center, University of California San Diego Health, La Jolla, California
| | - Barry Greenberg
- Sulpizio Cardiovascular Center, University of California San Diego Health, La Jolla, California
| | - Eric Adler
- Sulpizio Cardiovascular Center, University of California San Diego Health, La Jolla, California
| | - Vinay Thohan
- Aurora Cardiovascular Services, Aurora Sinai/Aurora St. Luke's Medical Centers, Milwaukee, Wisconsin
| |
Collapse
|
29
|
Gopinathannair R, Cornwell WK, Dukes JW, Ellis CR, Hickey KT, Joglar JA, Pagani FD, Roukoz H, Slaughter MS, Patton KK. Device Therapy and Arrhythmia Management in Left Ventricular Assist Device Recipients: A Scientific Statement From the American Heart Association. Circulation 2019; 139:e967-e989. [DOI: 10.1161/cir.0000000000000673] [Citation(s) in RCA: 66] [Impact Index Per Article: 13.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
Left ventricular assist devices (LVADs) are an increasingly used strategy for the management of patients with advanced heart failure with reduced ejection fraction. Although these devices effectively improve survival, atrial and ventricular arrhythmias are common, predispose these patients to additional risk, and complicate patient management. However, there is no consensus on best practices for the medical management of these arrhythmias or on the optimal timing for procedural interventions in patients with refractory arrhythmias. Although the vast majority of these patients have preexisting cardiovascular implantable electronic devices or cardiac resynchronization therapy, given the natural history of heart failure, it is common practice to maintain cardiovascular implantable electronic device detection and therapies after LVAD implantation. Available data, however, are conflicting on the efficacy of and optimal device programming after LVAD implantation. Therefore, the primary objective of this scientific statement is to review the available evidence and to provide guidance on the management of atrial and ventricular arrhythmias in this unique patient population, as well as procedural interventions and cardiovascular implantable electronic device and cardiac resynchronization therapy programming strategies, on the basis of a comprehensive literature review by electrophysiologists, heart failure cardiologists, cardiac surgeons, and cardiovascular nurse specialists with expertise in managing these patients. The structure and design of commercially available LVADs are briefly reviewed, as well as clinical indications for device implantation. The relevant physiological effects of long-term exposure to continuous-flow circulatory support are highlighted, as well as the mechanisms and clinical significance of arrhythmias in the setting of LVAD support.
Collapse
|
30
|
Moss JD, Oesterle A, Raiman M, Flatley EE, Beaser AD, Jeevanandam V, Klein L, Ota T, Wieselthaler G, Uriel N, Tung R. Feasibility and utility of intraoperative epicardial scar characterization during left ventricular assist device implantation. J Cardiovasc Electrophysiol 2018; 30:183-192. [PMID: 30516301 DOI: 10.1111/jce.13803] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/14/2018] [Revised: 10/29/2018] [Accepted: 11/06/2018] [Indexed: 02/03/2023]
Abstract
INTRODUCTION Ventricular arrhythmias (VA) after left ventricular assist device (LVAD) placement are associated with increased morbidity and mortality. We sought to assess epicardial voltage characteristics at the time of LVAD implantation and investigate relationships between scar burden and postimplant VA. METHODS AND RESULTS Consecutive patients underwent open chest epicardial electroanatomic mapping immediately before LVAD implantation. Areas of low voltage and sites with local abnormal potentials were identified. Patients were followed prospectively for postimplant VA and clinical outcomes. Between 2015 and 2017, 36 patients underwent high-density intraoperative epicardial voltage mapping; 15 had complete maps suitable for analysis. Mapping required a median of 11.8 (interquartile range [IQR], 8.5-12.7) minutes, with a median of 2650 (IQR, 2139-3191) points sampled per patient. Over a median follow-up of 311 (IQR, 168-469) postoperative days, four patients (27%) experienced sustained VA. Patients with postimplant VA were more likely to have had preimplant implantable cardioverter defibrillator shocks (100% vs 27%; P = 0.03), ventricular tachycardia storm (75% vs 9%; P = 0.03), and lower ejection fraction (13.5 vs 19.0%, P = 0.05). Patients with postimplant VA also had a significantly higher burden of epicardial low bipolar voltage points: 55.4% vs 24.9% of points were less than 0.5 mV (P = 0.01), and 88.9% vs 63.7% of points less than 1.5 mV (P = 0.004). CONCLUSIONS Intraoperative high-density epicardial mapping during LVAD implantation is safe and efficient, facilitating characterization of a potentially arrhythmogenic substrate. An increased burden of the epicardial scar may be associated with a higher incidence of postimplant VA. The role of empiric intraoperative epicardial ablation to mitigate risk of postimplant VA requires further study.
Collapse
Affiliation(s)
- Joshua D Moss
- Department of Medicine, Division of Cardiology, Section of Cardiac Electrophysiology, University of California San Francisco, San Francisco, California
| | - Adam Oesterle
- Department of Medicine, Division of Cardiology, Section of Cardiac Electrophysiology, University of California San Francisco, San Francisco, California
| | | | - Erin E Flatley
- Department of Medicine, Division of Cardiology, Section of Cardiac Electrophysiology, University of California San Francisco, San Francisco, California
| | - Andrew D Beaser
- Department of Medicine, Section of Cardiology, Center for Arrhythmia Care, University of Chicago Medicine, Chicago, Illinois
| | - Valluvan Jeevanandam
- Department of Surgery, Section of Cardiac and Thoracic Surgery, University of Chicago Medicine, Chicago, Illinois
| | - Liviu Klein
- Department of Medicine, Division of Cardiology, Section of Heart Failure, University of California San Francisco, San Francisco, California
| | - Takeyoshi Ota
- Department of Surgery, Section of Cardiac and Thoracic Surgery, University of Chicago Medicine, Chicago, Illinois
| | - Georg Wieselthaler
- Department of Surgery, Division of Adult Cardiothoracic Surgery, University of California San Francisco, San Francisco, California
| | - Nir Uriel
- Department of Medicine, Section of Cardiology, University of Chicago Medicine, Chicago, IL
| | - Roderick Tung
- Department of Medicine, Section of Cardiology, Center for Arrhythmia Care, University of Chicago Medicine, Chicago, Illinois
| |
Collapse
|
31
|
Catheter Ablation of Ventricular Tachycardia in Patients With a Ventricular Assist Device: A Systematic Review of Procedural Characteristics and Outcomes. JACC Clin Electrophysiol 2018; 5:39-51. [PMID: 30678785 DOI: 10.1016/j.jacep.2018.08.009] [Citation(s) in RCA: 30] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2018] [Revised: 08/07/2018] [Accepted: 08/17/2018] [Indexed: 01/17/2023]
Abstract
OBJECTIVES This is a systematic review summarizing the procedural characteristics and outcomes of ventricular assist device (VAD)-related ventricular tachycardia (VT) ablation. BACKGROUND Drug-refractory VT refractory commonly develops post-VAD implantation. Procedural and outcome data come from small series or case reports. METHODS An electronic search was performed using major databases. Primary outcomes were VT recurrence, mortality, and cardiac transplantation. Secondary endpoints were acute procedural success and procedural complications. RESULTS Eighteen studies were included, with a total of 110 patients (mean age 59.6 ± 11 years, 89% men; VT storm 34%). Scar-related re-entry was the predominant mechanism of VT (90.3%) and cannula-related VT in 19.3% cases. Electroanatomical mapping interference occurred in 1.8% of cases; there were no reports of catheter entrapment. Noninducibility of clinical VT was achieved in 77.9%; procedural complications occurred in 9.4%. At a mean follow-up of 263.5 ± 267.0 days, VT recurred in 43.6%, 23.4% underwent cardiac transplant, and 48.1% died. There were no procedural-related deaths and no death was directly related to ventricular arrhythmia. In follow-up, there was a significant reduction in implantable cardioverter-defibrillator therapies or shocks (57.1% vs. 23.8%). Ablation allowed VT storm termination in 90% of patients. CONCLUSIONS VAD-related VT is predominantly related to pre-existing intrinsic myocardial scar rather than inflow cannula site insertion. Catheter ablation is a reasonable treatment strategy, albeit with expectedly high rate of recurrence, transplantation, and mortality related to severe underlying disease.
Collapse
|
32
|
Galand V, Flécher E, Auffret V, Boulé S, Vincentelli A, Dambrin C, Mondoly P, Sacher F, Nubret K, Kindo M, Cardi T, Gaudard P, Rouvière P, Michel M, Gourraud JB, Defaye P, Chavanon O, Verdonk C, Ghodbane W, Pelcé E, Gariboldi V, Pozzi M, Obadia JF, Litzler PY, Anselme F, Babatasi G, Belin A, Garnier F, Bielefeld M, Hamon D, Radu C, Pierre B, Bourguignon T, Eschalier R, D'Ostrevy N, Bories MC, Marijon E, Vanhuyse F, Blangy H, Verhoye JP, Leclercq C, Martins RP. Predictors and Clinical Impact of Late Ventricular Arrhythmias in Patients With Continuous-Flow Left Ventricular Assist Devices. JACC Clin Electrophysiol 2018; 4:1166-1175. [PMID: 30236390 DOI: 10.1016/j.jacep.2018.05.006] [Citation(s) in RCA: 56] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2018] [Revised: 04/26/2018] [Accepted: 05/17/2018] [Indexed: 11/26/2022]
Abstract
OBJECTIVES This study aimed to evaluate the incidence, clinical impact, and predictors of late ventricular arrhythmias (VAs) in left ventricular assist device (LVAD) recipients aiming to clarify implantable cardioverter-defibrillator (ICD) indications. BACKGROUND The arrhythmic risk and need for ICD in patients implanted with an LVAD are not very well known. METHODS This observational study was conducted in 19 centers between 2006 and 2016. Late VAs were defined as sustained ventricular tachycardia or fibrillation occurring >30 days post-LVAD implantation, without acute reversible cause and requiring appropriate ICD therapy, external electrical shock, or medical therapy. RESULTS Among 659 LVAD recipients, 494 (median 58.9 years of age; mean left ventricular ejection fraction 20.7 ± 7.4%; 73.1% HeartMate II, 18.6% HeartWare, 8.3% Jarvik 2000) were discharged alive from hospital and included in the final analysis. Late VAs occurred in 133 (26.9%) patients. Multivariable analysis identified 6 independent predictors of late VAs: VAs before LVAD implantation, atrial fibrillation before LVAD implantation, idiopathic etiology of the cardiomyopathy, heart failure duration >12 months, early VAs (<30 days post-LVAD), and no angiotensin-converting enzyme inhibitors during follow-up. The "VT-LVAD score" was created, identifying 4 risk groups: low (score 0 to 1), intermediate (score 2 to 4), high (score 5 to 6), and very high (score 7 to 10). The rates of VAs at 1 year were 0.0%, 8.0%, 31.0% and 55.0%, respectively. CONCLUSIONS Late VAs are common after LVAD implantation. The VT-LVAD score may help to identify patients at risk of late VAs and guide ICD indications in previously nonimplanted patients. (Determination of Risk Factors of Ventricular Arrhythmias [VAs] after implantation of continuous flow left ventricular assist device with continuous flow left ventricular assist device [CF-LVAD] [ASSIST-ICD]; NCT02873169).
Collapse
Affiliation(s)
- Vincent Galand
- Service de Cardiologie et Maladies Vasculaires, CHU Rennes, Rennes, France; Université de Rennes 1, Rennes, France; U1099, INSERM, Rennes, France
| | - Erwan Flécher
- Université de Rennes 1, Rennes, France; Service de chirurgie cardiaque et thoracique, Rennes, France
| | - Vincent Auffret
- Service de Cardiologie et Maladies Vasculaires, CHU Rennes, Rennes, France; Université de Rennes 1, Rennes, France; U1099, INSERM, Rennes, France
| | - Stéphane Boulé
- Department of Cardiac Surgery, Department of Cardiology, Cardiac Intensive Care Unit, Institut Coeur-Poumons, CHU Lille, Lille, France
| | - André Vincentelli
- Department of Cardiac Surgery, Department of Cardiology, Cardiac Intensive Care Unit, Institut Coeur-Poumons, CHU Lille, Lille, France
| | - Camille Dambrin
- Service de Cardiologie, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
| | - Pierre Mondoly
- Service de Cardiologie, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
| | - Frédéric Sacher
- Service de Cardiologie, Hôpital Cardiologique du Haut-Lévêque, Université Bordeaux II, Bordeaux, France
| | - Karine Nubret
- Service de Cardiologie, Hôpital Cardiologique du Haut-Lévêque, Université Bordeaux II, Bordeaux, France
| | - Michel Kindo
- Département de chirurgie cardiovasculaire, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - Thomas Cardi
- Département de chirurgie cardiovasculaire, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - Philippe Gaudard
- Department of Cardiac Surgery, Anesthesiology and Critical Care Medicine, Arnaud de Villeneuve Hospital, CHRU Montpellier, Montpellier, France
| | - Philippe Rouvière
- Department of Cardiac Surgery, Anesthesiology and Critical Care Medicine, Arnaud de Villeneuve Hospital, CHRU Montpellier, Montpellier, France
| | - Magali Michel
- Department of Cardiology and Heart Transplantation Unit, CHU Nantes, Nantes, France
| | | | - Pascal Defaye
- Department of Cardiology and Cardiovascular Surgery, CHU Michallon, Grenoble, France
| | - Olivier Chavanon
- Department of Cardiology and Cardiovascular Surgery, CHU Michallon, Grenoble, France
| | - Constance Verdonk
- Department of Cardiology and Cardiac Surgery, Bichat-Hospital, Paris, France
| | - Walid Ghodbane
- Department of Cardiology and Cardiac Surgery, Bichat-Hospital, Paris, France
| | - Edeline Pelcé
- Department of Cardiac Surgery, La Timone Hospital, Marseille, France
| | - Vlad Gariboldi
- Department of Cardiac Surgery, La Timone Hospital, Marseille, France
| | - Matteo Pozzi
- Department of Cardiac Surgery, "Louis Pradel" Cardiologic Hospital, Lyon, France
| | - Jean-François Obadia
- Department of Cardiac Surgery, "Louis Pradel" Cardiologic Hospital, Lyon, France
| | - Pierre-Yves Litzler
- Department of Cardiology and Cardiovascular Surgery, Hospital Charles Nicolle, Rouen, France
| | - Frédéric Anselme
- Department of Cardiology and Cardiovascular Surgery, Hospital Charles Nicolle, Rouen, France
| | - Gerard Babatasi
- Department of Cardiology and Cardiac Surgery, University Hospital of Caen, University of Caen, Caen, France
| | - Annette Belin
- Department of Cardiology and Cardiac Surgery, University Hospital of Caen, University of Caen, Caen, France
| | - Fabien Garnier
- Department of Cardiology and Cardiac Surgery, University Hospital Dijon Bourgogne, Dijon, France
| | - Marie Bielefeld
- Department of Cardiology and Cardiac Surgery, University Hospital Dijon Bourgogne, Dijon, France
| | - David Hamon
- Department of Cardiology and Cardiac Surgery, AP-HP CHU Henri Mondor, Créteil, France
| | - Costin Radu
- Department of Cardiology and Cardiac Surgery, AP-HP CHU Henri Mondor, Créteil, France
| | - Bertrand Pierre
- Department of Cardiology and Cardiac Surgery, Tours University Hospital, Tours, France
| | - Thierry Bourguignon
- Department of Cardiology and Cardiac Surgery, Tours University Hospital, Tours, France
| | - Romain Eschalier
- Cardiology Department, CHU Clermont-Ferrand, Clermont-Ferrand, France
| | - Nicolas D'Ostrevy
- Cardiology Department, CHU Clermont-Ferrand, Clermont-Ferrand, France
| | | | - Eloi Marijon
- Cardiology Department, European Georges Pompidou Hospital, Paris, France
| | - Fabrice Vanhuyse
- Department of Cardiology and Cardiac Surgery, Hopital de Brabois, CHU de Nancy, Nancy, France
| | - Hugues Blangy
- Department of Cardiology and Cardiac Surgery, Hopital de Brabois, CHU de Nancy, Nancy, France
| | | | - Christophe Leclercq
- Service de Cardiologie et Maladies Vasculaires, CHU Rennes, Rennes, France; Université de Rennes 1, Rennes, France; U1099, INSERM, Rennes, France
| | - Raphaël P Martins
- Service de Cardiologie et Maladies Vasculaires, CHU Rennes, Rennes, France; Université de Rennes 1, Rennes, France; U1099, INSERM, Rennes, France.
| | | |
Collapse
|
33
|
Management of Arrhythmias and Cardiac Implantable Electronic Devices in Patients With Left Ventricular Assist Devices. JACC Clin Electrophysiol 2018; 4:847-859. [DOI: 10.1016/j.jacep.2018.04.014] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2018] [Revised: 04/28/2018] [Accepted: 04/30/2018] [Indexed: 11/21/2022]
|
34
|
Her K, Kim JY, Lim KM, Choi SW. Windkessel model of hemodynamic state supported by a pulsatile ventricular assist device in premature ventricle contraction. Biomed Eng Online 2018; 17:18. [PMID: 29394944 PMCID: PMC5797383 DOI: 10.1186/s12938-018-0440-5] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2017] [Accepted: 01/10/2018] [Indexed: 11/15/2022] Open
Abstract
Background Counter-pulsation control (CPC) by ventricular assist devices (VADs) is believed to reduce cardiac load and increase coronary perfusion. However, patients with VADs have a higher risk of arrhythmia, which may cause the CPC to fail. Consequently, CPC has not been applied by VADs in clinical practice. The phase-locked loop (PLL) algorithm for CPC is readily implemented in VADs; however, it requires a normal, consistent heartbeat for adequate performance. When an arrhythmia occurs, the algorithm maintains a constant pumping rate despite the unstable heartbeat. Therefore, to apply the PLL algorithm to CPC, the hemodynamic effects of abnormal heartbeats must be analyzed. Objectives This study sought to predict the hemodynamic effects in patients undergoing CPC using VADs, based on electrocardiogram (ECG) data, including a wide range of heart rate (HR) changes caused by premature ventricular contraction (PVC) or other reasons. Methods A four-element Windkessel hemodynamic model was used to reproduce the patient’s aortic blood pressure in this study. ECG data from 15 patients with severe congestive heart failure were used to assess the effect of the CPC on the patients’ hemodynamic state. The input and output flow characteristics of the pulsatile VAD (LibraHeart I, Cervika, Korea) were measured using an ultrasound blood flow meter (TS410, Transonic, USA), with the aortic pressure maintained at 80–120 mmHg. All other patient conditions were also reproduced. Results In patients with PVCs or normal heartbeats, CPC controlled by a VAD reduced the cardiac load by 20 and 40%, respectively. When the HR was greater for other reasons, such as sinus tachycardia, simultaneous ejection from the heart and VAD was observed; however, the cardiac load was not increased by rapid cardiac contractions resulting from decreased left ventricle volume. These data suggest that the PLL algorithm reduces the cardiac load and maintains consistent hemodynamic changes.
Collapse
Affiliation(s)
- Keun Her
- Department of Cardiovascular and Thoracic Surgery, Soonchunhyang University Hospital, Bucheon-si, Republic of Korea
| | - Joon Yeong Kim
- Program of Mechanical and Biomedical Engineering, College of Engineering, Kangwon National University, Chuncheon-si, Republic of Korea
| | - Ki Moo Lim
- Department of Medical IT Convergence Engineering, Kumoh National Institute of Technology, Gumi, Republic of Korea
| | - Seong Wook Choi
- Program of Mechanical and Biomedical Engineering, College of Engineering, Kangwon National University, Chuncheon-si, Republic of Korea.
| |
Collapse
|
35
|
Kadado AJ, Akar JG, Hummel JP. Arrhythmias after left ventricular assist device implantation: Incidence and management. Trends Cardiovasc Med 2018; 28:41-50. [DOI: 10.1016/j.tcm.2017.07.002] [Citation(s) in RCA: 25] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/26/2017] [Revised: 07/04/2017] [Accepted: 07/04/2017] [Indexed: 10/19/2022]
|
36
|
Corre J, Picard F, Garcia R, Zemmoura A, Derval N, Denis A, Romen A, Nubret K, Jais P, Haissaguerre M, Dos Santos P, Barandon L, Sacher F. Electrical storm in the early phase of HeartMate ® II device implantation: Incidence, risk factors and prognosis. Arch Cardiovasc Dis 2017; 111:332-339. [PMID: 29217463 DOI: 10.1016/j.acvd.2017.07.006] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/23/2017] [Revised: 07/31/2017] [Accepted: 07/31/2017] [Indexed: 11/19/2022]
Abstract
BACKGROUND Ventricular arrhythmia is common after left ventricular assist device (LVAD) implantation, especially in the early postoperative phase (<30 days). AIM To identify the incidence of and risk factors for electrical storm (ES) occurring within 30 days of HeartMate® II implantation. METHODS We reviewed data from all consecutive patients undergoing HeartMate® II device implantation at our institution from January 2008 to December 2014. Patient demographic data, pharmacotherapies and outcomes were collected. The primary endpoint was occurrence of early ES (within 30 days of surgery), defined as three or more separate episodes of sustained ventricular arrhythmia within a 24-hour interval, requiring appropriate therapy. RESULTS Forty-three patients (mean age 56.7±11.2 years; 39 men) were included. At HeartMate® II implantation, mean left ventricular ejection fraction was 20±5%, 32 (74.4%) patients had ischaemic cardiomyopathy and 31 (72.1%) were implanted with an indication of bridge to cardiac transplantation. During follow-up, 12 (27.9%) patients experienced early ES after HeartMate® II implantation (median delay 9.1±7.8 days). Early ES was more frequent in larger patients (body surface area 1.99 vs 1.81 m2; P<0.01), tended to be associated with previous sustained ventricular tachycardia (50.0% vs 22.6%; P=0.08), previous implantable cardioverter-defibrillator implantation (66.7% vs 38.7%; P=0.09), discontinuation of long-term beta-blocker therapy (75.0% vs 45.2%; P=0.08), weaning of adrenergic drugs after the third day (66.7% vs 35.5%; P=0.06) and the use of extracorporeal life support (50% vs 22.6%; P=0.079), but was not associated with the cardiomyopathy aetiology or the indication for assistance. Catheter ventricular tachycardia ablation was performed in six (14.0%) patients. Early ES was associated with a significantly higher all-cause mortality rate at the 30th day (33.3% vs 6.5%; P=0.02). CONCLUSION ES is a common and pejorative feature in the early postoperative period.
Collapse
Affiliation(s)
- Jerome Corre
- Service de rythmologie, hôpital cardiologique du Haut-Lévêque, 1, avenue Magellan, 33600 Pessac, France.
| | - François Picard
- Service d'insuffisance cardiaque, hôpital cardiologique du Haut-Lévêque, 33600 Pessac, France
| | - Rodrigue Garcia
- Service de rythmologie, hôpital cardiologique du Haut-Lévêque, 1, avenue Magellan, 33600 Pessac, France
| | - Adlane Zemmoura
- Service de rythmologie, hôpital cardiologique du Haut-Lévêque, 1, avenue Magellan, 33600 Pessac, France
| | - Nicolas Derval
- Service de rythmologie, hôpital cardiologique du Haut-Lévêque, 1, avenue Magellan, 33600 Pessac, France
| | - Arnaud Denis
- Service de rythmologie, hôpital cardiologique du Haut-Lévêque, 1, avenue Magellan, 33600 Pessac, France; LIRYC Institute, Inserm 1045, University of Bordeaux, Bordeaux, France
| | - Antoine Romen
- Service d'insuffisance cardiaque, hôpital cardiologique du Haut-Lévêque, 33600 Pessac, France
| | - Karine Nubret
- Service d'insuffisance cardiaque, hôpital cardiologique du Haut-Lévêque, 33600 Pessac, France
| | - Pierre Jais
- Service de rythmologie, hôpital cardiologique du Haut-Lévêque, 1, avenue Magellan, 33600 Pessac, France; LIRYC Institute, Inserm 1045, University of Bordeaux, Bordeaux, France
| | - Michel Haissaguerre
- Service de rythmologie, hôpital cardiologique du Haut-Lévêque, 1, avenue Magellan, 33600 Pessac, France; LIRYC Institute, Inserm 1045, University of Bordeaux, Bordeaux, France
| | - Pierre Dos Santos
- Service de rythmologie, hôpital cardiologique du Haut-Lévêque, 1, avenue Magellan, 33600 Pessac, France
| | - Laurent Barandon
- Service de chirurgie cardiaque, hôpital cardiologique du Haut-Lévêque, Pessac, France
| | - Frederic Sacher
- Service de rythmologie, hôpital cardiologique du Haut-Lévêque, 1, avenue Magellan, 33600 Pessac, France; LIRYC Institute, Inserm 1045, University of Bordeaux, Bordeaux, France
| |
Collapse
|
37
|
Arrhythmias in Patients with Cardiac Implantable Electrical Devices after Implantation of a Left Ventricular Assist Device. ASAIO J 2017; 62:274-80. [PMID: 26809088 DOI: 10.1097/mat.0000000000000349] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
Utilization of continuous-flow left ventricular assist devices (CF-LVADs) for advanced heart failure is increasing, and the role of cardiac implantable electrical devices (CIED) is unclear. Prior studies of the incidence of arrhythmias and shocks are frequently limited by ascertainment. One hundred and seventy-eight patients were examined with a previous CIED who were implanted with a CF-LVAD. Medical history, medications, and CIED data from device interrogations were gathered. A cardiac surgery control group (n = 38) was obtained to control for surgical factors. Several clinically significant events increased after LVAD implantation: treated-zone ventricular arrhythmias (VA; p < 0.01), monitored-zone VA (p < 0.01), antitachycardia pacing (ATP)-terminated episodes (p < 0.01), and shocks (p = 0.01), although administered shocks later decreased (p < 0.01). Presence of a preimplant VA was associated with postoperative VA (odds ratio [OR]: 4.31; confidence interval [CI]: 1.5-12.3, p < 0.01). Relative to cardiac surgery, LVAD patients experienced more perioperative events (i.e., monitored VAs and shocks, p < 0.01 and p = 0.04). Neither implantable cardioverter defibrillator (ICD) shocks before implant nor early or late postimplant arrhythmias or shocks predicted survival (p = 0.07, p = 0.55, and p = 0.55). Our experience demonstrates time-dependent effects on clinically significant arrhythmias after LVAD implantation, including evidence that early LVAD-related arrhythmias may be caused by the unique arrhythmogenic effects of VAD implant.
Collapse
|
38
|
Santangeli P, Rame JE, Birati EY, Marchlinski FE. Management of Ventricular Arrhythmias in Patients With Advanced Heart Failure. J Am Coll Cardiol 2017; 69:1842-1860. [DOI: 10.1016/j.jacc.2017.01.047] [Citation(s) in RCA: 49] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/15/2016] [Revised: 01/19/2017] [Accepted: 01/23/2017] [Indexed: 02/08/2023]
|
39
|
Kang SM, Her K, Choi SW. Outflow monitoring of a pneumatic ventricular assist device using external pressure sensors. Biomed Eng Online 2016; 15:100. [PMID: 27562439 PMCID: PMC5000458 DOI: 10.1186/s12938-016-0204-z] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2016] [Accepted: 07/04/2016] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND In this study, a new algorithm was developed for estimating the pump outflow of a pneumatic ventricular assist device (p-VAD). The pump outflow estimation algorithm was derived from the ideal gas equation and determined the change in blood-sac volume of a p-VAD using two external pressure sensors. OBJECTIVES Based on in vitro experiments, the algorithm was revised to consider the effects of structural compliance caused by volume changes in an implanted unit, an air driveline, and the pressure difference between the sensors and the implanted unit. METHODS In animal experiments, p-VADs were connected to the left ventricles and the descending aorta of three calves (70-100 kg). Their outflows were estimated using the new algorithm and compared to the results obtained using an ultrasonic blood flow meter (UBF) (TS-410, Transonic Systems Inc., Ithaca, NY, USA). RESULTS The estimated and measured values had a Pearson's correlation coefficient of 0.864. The pressure sensors were installed at the external controller and connected to the air driveline on the same side as the external actuator, which made the sensors easy to manage.
Collapse
Affiliation(s)
- Seong Min Kang
- Department of Mechanical and Biomedical Engineering, College of Engineering, Kangwon National University, 192-1 Hyoja-Dong, Chuncheon-si, South Korea
| | - Keun Her
- Department of Cardiovascular and Thoracic Surgery, Soonchunhyang University Hospital, Bucheon-si, South Korea
| | - Seong Wook Choi
- Department of Mechanical and Biomedical Engineering, College of Engineering, Kangwon National University, 192-1 Hyoja-Dong, Chuncheon-si, South Korea.
| |
Collapse
|
40
|
Agrawal S, Garg L, Nanda S, Sharma A, Bhatia N, Manda Y, Singh A, Fegley M, Shirani J. The role of implantable cardioverter-defibrillators in patients with continuous flow left ventricular assist devices - A meta-analysis. Int J Cardiol 2016; 222:379-384. [PMID: 27505320 DOI: 10.1016/j.ijcard.2016.07.257] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/19/2016] [Revised: 07/12/2016] [Accepted: 07/30/2016] [Indexed: 11/30/2022]
Abstract
BACKGROUND Left ventricular assist devices (LVADs) and implantable cardioverter defibrillators (ICD) are each known to improve mortality in patients with advanced congestive heart failure (CHF). If ICDs contribute to improved survival specifically in recipients of LVADs is currently unknown. AIM To evaluate the impact of presence of ICD on mortality in continuous flow LVAD recipients. METHODS A meta- analysis of available literature was performed. PubMed, Embase and Google Scholar databases were searched for studies that compared mortality in continuous flow LVAD patients with ICDs (new implantation or no de-activation) and without ICDs (including de-activation of existing implant). Pooled analysis using a fixed effects model was used for outcomes of interest. RESULTS We included 3 observational studies for a total of 292 patients (203 (69.5%) with ICD versus 89 (30.5%) without ICD). The presence of an active ICD was not associated with improved survival [OR 0.63, 95% CI 0.33-1.18; p=0.15]. In bridge to transplantation [BT] patients (224 patients, 149 with ICD versus 75 without ICD), an active ICD was not associated with a higher probability of survivzal [OR 1.47, 95% CI 0.78-2.76; p=0.23]. There was no difference in the occurrence of severe right ventricular dysfunction or failure between two groups [OR 0.78, 95% CI 0.42-1.47; p=0.45]. The risk of LVAD related complications were similar [OR 0.68, 95% CI 0.35-1.31; P=0.25]. CONCLUSION This meta-analysis demonstrates that there is no survival benefit with ICD in heart failure patients supported with continuous flow LVAD. There is an urgent need of large-scale randomized trials to specifically address this issue.
Collapse
Affiliation(s)
- Sahil Agrawal
- Division of Cardiology, Department of Medicine, St. Luke's University Health Network, Bethlehem, PA 18015, USA.
| | - Lohit Garg
- Department of Medicine, Beaumont Health System, Royal Oak, MI, USA
| | - Sudip Nanda
- Division of Cardiology, Department of Medicine, St. Luke's University Health Network, Bethlehem, PA 18015, USA
| | - Abhishek Sharma
- Division of Cardiology, Department of Medicine, State University of New York Downstate Medical Center, Brooklyn, NY 11203, USA
| | - Nirmanmoh Bhatia
- Division of Cardiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA
| | - Yugandhar Manda
- Division of Cardiology, Department of Medicine, St. Luke's University Health Network, Bethlehem, PA 18015, USA
| | - Amitoj Singh
- Division of Cardiology, Department of Medicine, St. Luke's University Health Network, Bethlehem, PA 18015, USA
| | - Mark Fegley
- Division of Cardiology, Department of Medicine, St. Luke's University Health Network, Bethlehem, PA 18015, USA
| | - Jamshid Shirani
- Division of Cardiology, Department of Medicine, St. Luke's University Health Network, Bethlehem, PA 18015, USA
| |
Collapse
|
41
|
Sen A, Larson JS, Kashani KB, Libricz SL, Patel BM, Guru PK, Alwardt CM, Pajaro O, Farmer JC. Mechanical circulatory assist devices: a primer for critical care and emergency physicians. CRITICAL CARE : THE OFFICIAL JOURNAL OF THE CRITICAL CARE FORUM 2016; 20:153. [PMID: 27342573 PMCID: PMC4921031 DOI: 10.1186/s13054-016-1328-z] [Citation(s) in RCA: 67] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Mechanical circulatory assist devices are now commonly used in the treatment of severe heart failure as bridges to cardiac transplant, as destination therapy for patients who are not transplant candidates, and as bridges to recovery and “decision-making”. These devices, which can be used to support the left or right ventricles or both, restore circulation to the tissues, thereby improving organ function. Left ventricular assist devices (LVADs) are the most common support devices. To care for patients with these devices, health care providers in emergency departments (EDs) and intensive care units (ICUs) need to understand the physiology of the devices, the vocabulary of mechanical support, the types of complications patients may have, diagnostic techniques, and decision-making regarding treatment. Patients with LVADs who come to the ED or are admitted to the ICU usually have nonspecific clinical symptoms, most commonly shortness of breath, hypotension, anemia, chest pain, syncope, hemoptysis, gastrointestinal bleeding, jaundice, fever, oliguria and hematuria, altered mental status, headache, seizure, and back pain. Other patients are seen for cardiac arrest, psychiatric issues, sequelae of noncardiac surgery, and trauma. Although most patients have LVADs, some may have biventricular support devices or total artificial hearts. Involving a team of cardiac surgeons, perfusion experts, and heart-failure physicians, as well as ED and ICU physicians and nurses, is critical for managing treatment for these patients and for successful outcomes. This review is designed for critical care providers who may be the first to see these patients in the ED or ICU.
Collapse
Affiliation(s)
- Ayan Sen
- Department of Critical Care Medicine, Mayo Clinic Hospital, 5777 E. Mayo Blvd, Phoenix, AZ, 85054, USA.
| | - Joel S Larson
- Department of Critical Care Medicine, Mayo Clinic Hospital, 5777 E. Mayo Blvd, Phoenix, AZ, 85054, USA
| | - Kianoush B Kashani
- Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.,Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota, USA
| | - Stacy L Libricz
- Department of Critical Care Medicine, Mayo Clinic Hospital, 5777 E. Mayo Blvd, Phoenix, AZ, 85054, USA
| | - Bhavesh M Patel
- Department of Critical Care Medicine, Mayo Clinic Hospital, 5777 E. Mayo Blvd, Phoenix, AZ, 85054, USA
| | - Pramod K Guru
- Department of Critical Care Medicine, Mayo Clinic Jacksonville, Florida, USA
| | - Cory M Alwardt
- Division of Cardiovascular and Thoracic Surgery, Mayo Clinic Hospital, Phoenix, Arizona, USA
| | - Octavio Pajaro
- Division of Cardiovascular and Thoracic Surgery, Mayo Clinic Hospital, Phoenix, Arizona, USA
| | - J Christopher Farmer
- Department of Critical Care Medicine, Mayo Clinic Hospital, 5777 E. Mayo Blvd, Phoenix, AZ, 85054, USA
| |
Collapse
|
42
|
Ruckdeschel ES, Wolfel E, Nguyen DT. A Case of Cough-induced Ventricular Tachycardia in a Patient with a Left Ventricular Assist Device. Card Electrophysiol Clin 2016; 8:165-167. [PMID: 26920187 DOI: 10.1016/j.ccep.2015.10.019] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
In this case, the patient's ventricular tachycardia (VT) was specifically induced by coughing, which has not previously been described. Decreasing the rotational speed of the left ventricular assist device (LVAD) and increasing preload by stopping the patient's nitrates and reducing diuretic dose allowed improved filling of the left ventricle (LV) and increased LV volumes. When coughing recurred, the effects on the LV cavity were less pronounced and thus VT was reduced. Although ventricular arrhythmias are common after LVAD placement, this is a unique case in which VT was caused by coughing, which is ordinarily not considered arrhythmogenic.
Collapse
Affiliation(s)
- Emily Sue Ruckdeschel
- Section of Electrophysiology, Cardiology Division, University of Colorado, Aurora, CO, USA
| | - Eugene Wolfel
- Section of Electrophysiology, Cardiology Division, University of Colorado, Aurora, CO, USA
| | - Duy Thai Nguyen
- Section of Electrophysiology, Cardiology Division, University of Colorado, Aurora, CO, USA.
| |
Collapse
|
43
|
Berthiaume J, Kirk J, Ranek M, Lyon R, Sheikh F, Jensen B, Hoit B, Butany J, Tolend M, Rao V, Willis M. Pathophysiology of Heart Failure and an Overview of Therapies. Cardiovasc Pathol 2016. [DOI: 10.1016/b978-0-12-420219-1.00008-2] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
|
44
|
Vega EA, Miko Enomoto T. Complications Following Left Ventricular Assist Device Implantation: Diagnosis and Management of Common Adverse Events. CURRENT ANESTHESIOLOGY REPORTS 2015. [DOI: 10.1007/s40140-015-0127-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
45
|
Physiologic outcome of varying speed rotary blood pump support algorithms: a review study. AUSTRALASIAN PHYSICAL & ENGINEERING SCIENCES IN MEDICINE 2015; 39:13-28. [DOI: 10.1007/s13246-015-0405-y] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/07/2015] [Accepted: 11/05/2015] [Indexed: 10/22/2022]
|
46
|
Lip GYH, Heinzel FR, Gaita F, Juanatey JRG, Le Heuzey JY, Potpara T, Svendsen JH, Vos MA, Anker SD, Coats AJ, Haverkamp W, Manolis AS, Chung MK, Sanders P, Pieske B. European Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. Eur J Heart Fail 2015; 17:848-74. [PMID: 26293171 DOI: 10.1002/ejhf.338] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
47
|
Lip GYH, Heinzel FR, Gaita F, Juanatey JRG, Le Heuzey JY, Potpara T, Svendsen JH, Vos MA, Anker SD, Coats AJ, Haverkamp W, Manolis AS, Chung MK, Sanders P, Pieske B, Gorenek B, Lane D, Boriani G, Linde C, Hindricks G, Tsutsui H, Homma S, Brownstein S, Nielsen JC, Lainscak M, Crespo-Leiro M, Piepoli M, Seferovic P, Savelieva I. European Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. Europace 2015; 18:12-36. [PMID: 26297713 DOI: 10.1093/europace/euv191] [Citation(s) in RCA: 45] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
|
48
|
|
49
|
Sacher F, Reichlin T, Zado ES, Field ME, Viles-Gonzalez JF, Peichl P, Ellenbogen KA, Maury P, Dukkipati SR, Picard F, Kautzner J, Barandon L, Koneru JN, Ritter P, Mahida S, Calderon J, Derval N, Denis A, Cochet H, Shepard RK, Corre J, Coffey JO, Garcia F, Hocini M, Tedrow U, Haissaguerre M, d'Avila A, Stevenson WG, Marchlinski FE, Jais P. Characteristics of ventricular tachycardia ablation in patients with continuous flow left ventricular assist devices. Circ Arrhythm Electrophysiol 2015; 8:592-7. [PMID: 25870335 DOI: 10.1161/circep.114.002394] [Citation(s) in RCA: 63] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/10/2014] [Accepted: 03/30/2015] [Indexed: 11/16/2022]
Abstract
BACKGROUND Left ventricular assist devices (LVADs) are increasingly used as a bridge to cardiac transplantation or as destination therapy. Patients with LVADs are at high risk for ventricular arrhythmias. This study describes ventricular arrhythmia characteristics and ablation in patients implanted with a Heart Mate II device. METHODS AND RESULTS All patients with a Heart Mate II device who underwent ventricular arrhythmia catheter ablation at 9 tertiary centers were included. Thirty-four patients (30 male, age 58±10 years) underwent 39 ablation procedures. The underlying cardiomyopathy pathogenesis was ischemic in 21 and nonischemic in 13 patients with a mean left ventricular ejection fraction of 17%±5% before LVAD implantation. One hundred and ten ventricular tachycardias (VTs; cycle lengths, 230-740 ms, arrhythmic storm n=28) and 2 ventricular fibrillation triggers were targeted (25 transseptal, 14 retrograde aortic approaches). Nine patients required VT ablation <1 month after LVAD implantation because of intractable VT. Only 10/110 (9%) of the targeted VTs were related to the Heart Mate II cannula. During follow-up, 7 patients were transplanted and 10 died. Of the remaining 17 patients, 13 were arrhythmia-free at 25±15 months. In 1 patient with VT recurrence, change of turbine speed from 9400 to 9000 rpm extinguished VT. CONCLUSIONS Catheter ablation of VT among LVAD recipients is feasible and reasonably safe even soon after LVAD implantation. Intrinsic myocardial scar, rather than the apical cannula, seems to be the dominant substrate.
Collapse
Affiliation(s)
- Frederic Sacher
- From the Bordeaux University Hospital/LIRYC institute/INSERM 1045/Bordeaux University, Bordeaux, France (F.S., F.P., L.B., P.R., J.C., N.D., A.D., H.C., J.C., M.H., M.H., P.J.); Brigham and Women Hospital, Boston, MA (T.R., S.M., U.T., W.G.S.); Electrophysiology Section, Cardiovascular Division, Hospital of the University of Pennsylvania, Philadelphia (E.S.Z., F.G., F.E.M.); Division of Cardiovascular Medicine, University of Wisconsin Hospital, Madison (M.E.F.); Department of Cardiac Electrophysiology, University of Miami Medical Center, FL (J.F.V.-G., J.O.C.); Institute for Clinical and Experimental Medicine, Prague, Czech Republic (P.P., J.K.); Division of Cardiology, Department of Medicine, Medical College of Virginia/Virginia Commonwealth University School of Medicine, Richmond (K.A.E., J.N.K., R.K.S.); CHU de Toulouse, Toulouse, France (P.M.); and Mount Sinai Hospital, New York, NY (S.R.D., A.d'A.).
| | - Tobias Reichlin
- From the Bordeaux University Hospital/LIRYC institute/INSERM 1045/Bordeaux University, Bordeaux, France (F.S., F.P., L.B., P.R., J.C., N.D., A.D., H.C., J.C., M.H., M.H., P.J.); Brigham and Women Hospital, Boston, MA (T.R., S.M., U.T., W.G.S.); Electrophysiology Section, Cardiovascular Division, Hospital of the University of Pennsylvania, Philadelphia (E.S.Z., F.G., F.E.M.); Division of Cardiovascular Medicine, University of Wisconsin Hospital, Madison (M.E.F.); Department of Cardiac Electrophysiology, University of Miami Medical Center, FL (J.F.V.-G., J.O.C.); Institute for Clinical and Experimental Medicine, Prague, Czech Republic (P.P., J.K.); Division of Cardiology, Department of Medicine, Medical College of Virginia/Virginia Commonwealth University School of Medicine, Richmond (K.A.E., J.N.K., R.K.S.); CHU de Toulouse, Toulouse, France (P.M.); and Mount Sinai Hospital, New York, NY (S.R.D., A.d'A.)
| | - Erica S Zado
- From the Bordeaux University Hospital/LIRYC institute/INSERM 1045/Bordeaux University, Bordeaux, France (F.S., F.P., L.B., P.R., J.C., N.D., A.D., H.C., J.C., M.H., M.H., P.J.); Brigham and Women Hospital, Boston, MA (T.R., S.M., U.T., W.G.S.); Electrophysiology Section, Cardiovascular Division, Hospital of the University of Pennsylvania, Philadelphia (E.S.Z., F.G., F.E.M.); Division of Cardiovascular Medicine, University of Wisconsin Hospital, Madison (M.E.F.); Department of Cardiac Electrophysiology, University of Miami Medical Center, FL (J.F.V.-G., J.O.C.); Institute for Clinical and Experimental Medicine, Prague, Czech Republic (P.P., J.K.); Division of Cardiology, Department of Medicine, Medical College of Virginia/Virginia Commonwealth University School of Medicine, Richmond (K.A.E., J.N.K., R.K.S.); CHU de Toulouse, Toulouse, France (P.M.); and Mount Sinai Hospital, New York, NY (S.R.D., A.d'A.)
| | - Michael E Field
- From the Bordeaux University Hospital/LIRYC institute/INSERM 1045/Bordeaux University, Bordeaux, France (F.S., F.P., L.B., P.R., J.C., N.D., A.D., H.C., J.C., M.H., M.H., P.J.); Brigham and Women Hospital, Boston, MA (T.R., S.M., U.T., W.G.S.); Electrophysiology Section, Cardiovascular Division, Hospital of the University of Pennsylvania, Philadelphia (E.S.Z., F.G., F.E.M.); Division of Cardiovascular Medicine, University of Wisconsin Hospital, Madison (M.E.F.); Department of Cardiac Electrophysiology, University of Miami Medical Center, FL (J.F.V.-G., J.O.C.); Institute for Clinical and Experimental Medicine, Prague, Czech Republic (P.P., J.K.); Division of Cardiology, Department of Medicine, Medical College of Virginia/Virginia Commonwealth University School of Medicine, Richmond (K.A.E., J.N.K., R.K.S.); CHU de Toulouse, Toulouse, France (P.M.); and Mount Sinai Hospital, New York, NY (S.R.D., A.d'A.)
| | - Juan F Viles-Gonzalez
- From the Bordeaux University Hospital/LIRYC institute/INSERM 1045/Bordeaux University, Bordeaux, France (F.S., F.P., L.B., P.R., J.C., N.D., A.D., H.C., J.C., M.H., M.H., P.J.); Brigham and Women Hospital, Boston, MA (T.R., S.M., U.T., W.G.S.); Electrophysiology Section, Cardiovascular Division, Hospital of the University of Pennsylvania, Philadelphia (E.S.Z., F.G., F.E.M.); Division of Cardiovascular Medicine, University of Wisconsin Hospital, Madison (M.E.F.); Department of Cardiac Electrophysiology, University of Miami Medical Center, FL (J.F.V.-G., J.O.C.); Institute for Clinical and Experimental Medicine, Prague, Czech Republic (P.P., J.K.); Division of Cardiology, Department of Medicine, Medical College of Virginia/Virginia Commonwealth University School of Medicine, Richmond (K.A.E., J.N.K., R.K.S.); CHU de Toulouse, Toulouse, France (P.M.); and Mount Sinai Hospital, New York, NY (S.R.D., A.d'A.)
| | - Petr Peichl
- From the Bordeaux University Hospital/LIRYC institute/INSERM 1045/Bordeaux University, Bordeaux, France (F.S., F.P., L.B., P.R., J.C., N.D., A.D., H.C., J.C., M.H., M.H., P.J.); Brigham and Women Hospital, Boston, MA (T.R., S.M., U.T., W.G.S.); Electrophysiology Section, Cardiovascular Division, Hospital of the University of Pennsylvania, Philadelphia (E.S.Z., F.G., F.E.M.); Division of Cardiovascular Medicine, University of Wisconsin Hospital, Madison (M.E.F.); Department of Cardiac Electrophysiology, University of Miami Medical Center, FL (J.F.V.-G., J.O.C.); Institute for Clinical and Experimental Medicine, Prague, Czech Republic (P.P., J.K.); Division of Cardiology, Department of Medicine, Medical College of Virginia/Virginia Commonwealth University School of Medicine, Richmond (K.A.E., J.N.K., R.K.S.); CHU de Toulouse, Toulouse, France (P.M.); and Mount Sinai Hospital, New York, NY (S.R.D., A.d'A.)
| | - Kenneth A Ellenbogen
- From the Bordeaux University Hospital/LIRYC institute/INSERM 1045/Bordeaux University, Bordeaux, France (F.S., F.P., L.B., P.R., J.C., N.D., A.D., H.C., J.C., M.H., M.H., P.J.); Brigham and Women Hospital, Boston, MA (T.R., S.M., U.T., W.G.S.); Electrophysiology Section, Cardiovascular Division, Hospital of the University of Pennsylvania, Philadelphia (E.S.Z., F.G., F.E.M.); Division of Cardiovascular Medicine, University of Wisconsin Hospital, Madison (M.E.F.); Department of Cardiac Electrophysiology, University of Miami Medical Center, FL (J.F.V.-G., J.O.C.); Institute for Clinical and Experimental Medicine, Prague, Czech Republic (P.P., J.K.); Division of Cardiology, Department of Medicine, Medical College of Virginia/Virginia Commonwealth University School of Medicine, Richmond (K.A.E., J.N.K., R.K.S.); CHU de Toulouse, Toulouse, France (P.M.); and Mount Sinai Hospital, New York, NY (S.R.D., A.d'A.)
| | - Philippe Maury
- From the Bordeaux University Hospital/LIRYC institute/INSERM 1045/Bordeaux University, Bordeaux, France (F.S., F.P., L.B., P.R., J.C., N.D., A.D., H.C., J.C., M.H., M.H., P.J.); Brigham and Women Hospital, Boston, MA (T.R., S.M., U.T., W.G.S.); Electrophysiology Section, Cardiovascular Division, Hospital of the University of Pennsylvania, Philadelphia (E.S.Z., F.G., F.E.M.); Division of Cardiovascular Medicine, University of Wisconsin Hospital, Madison (M.E.F.); Department of Cardiac Electrophysiology, University of Miami Medical Center, FL (J.F.V.-G., J.O.C.); Institute for Clinical and Experimental Medicine, Prague, Czech Republic (P.P., J.K.); Division of Cardiology, Department of Medicine, Medical College of Virginia/Virginia Commonwealth University School of Medicine, Richmond (K.A.E., J.N.K., R.K.S.); CHU de Toulouse, Toulouse, France (P.M.); and Mount Sinai Hospital, New York, NY (S.R.D., A.d'A.)
| | - Srinivas R Dukkipati
- From the Bordeaux University Hospital/LIRYC institute/INSERM 1045/Bordeaux University, Bordeaux, France (F.S., F.P., L.B., P.R., J.C., N.D., A.D., H.C., J.C., M.H., M.H., P.J.); Brigham and Women Hospital, Boston, MA (T.R., S.M., U.T., W.G.S.); Electrophysiology Section, Cardiovascular Division, Hospital of the University of Pennsylvania, Philadelphia (E.S.Z., F.G., F.E.M.); Division of Cardiovascular Medicine, University of Wisconsin Hospital, Madison (M.E.F.); Department of Cardiac Electrophysiology, University of Miami Medical Center, FL (J.F.V.-G., J.O.C.); Institute for Clinical and Experimental Medicine, Prague, Czech Republic (P.P., J.K.); Division of Cardiology, Department of Medicine, Medical College of Virginia/Virginia Commonwealth University School of Medicine, Richmond (K.A.E., J.N.K., R.K.S.); CHU de Toulouse, Toulouse, France (P.M.); and Mount Sinai Hospital, New York, NY (S.R.D., A.d'A.)
| | - Francois Picard
- From the Bordeaux University Hospital/LIRYC institute/INSERM 1045/Bordeaux University, Bordeaux, France (F.S., F.P., L.B., P.R., J.C., N.D., A.D., H.C., J.C., M.H., M.H., P.J.); Brigham and Women Hospital, Boston, MA (T.R., S.M., U.T., W.G.S.); Electrophysiology Section, Cardiovascular Division, Hospital of the University of Pennsylvania, Philadelphia (E.S.Z., F.G., F.E.M.); Division of Cardiovascular Medicine, University of Wisconsin Hospital, Madison (M.E.F.); Department of Cardiac Electrophysiology, University of Miami Medical Center, FL (J.F.V.-G., J.O.C.); Institute for Clinical and Experimental Medicine, Prague, Czech Republic (P.P., J.K.); Division of Cardiology, Department of Medicine, Medical College of Virginia/Virginia Commonwealth University School of Medicine, Richmond (K.A.E., J.N.K., R.K.S.); CHU de Toulouse, Toulouse, France (P.M.); and Mount Sinai Hospital, New York, NY (S.R.D., A.d'A.)
| | - Josef Kautzner
- From the Bordeaux University Hospital/LIRYC institute/INSERM 1045/Bordeaux University, Bordeaux, France (F.S., F.P., L.B., P.R., J.C., N.D., A.D., H.C., J.C., M.H., M.H., P.J.); Brigham and Women Hospital, Boston, MA (T.R., S.M., U.T., W.G.S.); Electrophysiology Section, Cardiovascular Division, Hospital of the University of Pennsylvania, Philadelphia (E.S.Z., F.G., F.E.M.); Division of Cardiovascular Medicine, University of Wisconsin Hospital, Madison (M.E.F.); Department of Cardiac Electrophysiology, University of Miami Medical Center, FL (J.F.V.-G., J.O.C.); Institute for Clinical and Experimental Medicine, Prague, Czech Republic (P.P., J.K.); Division of Cardiology, Department of Medicine, Medical College of Virginia/Virginia Commonwealth University School of Medicine, Richmond (K.A.E., J.N.K., R.K.S.); CHU de Toulouse, Toulouse, France (P.M.); and Mount Sinai Hospital, New York, NY (S.R.D., A.d'A.)
| | - Laurent Barandon
- From the Bordeaux University Hospital/LIRYC institute/INSERM 1045/Bordeaux University, Bordeaux, France (F.S., F.P., L.B., P.R., J.C., N.D., A.D., H.C., J.C., M.H., M.H., P.J.); Brigham and Women Hospital, Boston, MA (T.R., S.M., U.T., W.G.S.); Electrophysiology Section, Cardiovascular Division, Hospital of the University of Pennsylvania, Philadelphia (E.S.Z., F.G., F.E.M.); Division of Cardiovascular Medicine, University of Wisconsin Hospital, Madison (M.E.F.); Department of Cardiac Electrophysiology, University of Miami Medical Center, FL (J.F.V.-G., J.O.C.); Institute for Clinical and Experimental Medicine, Prague, Czech Republic (P.P., J.K.); Division of Cardiology, Department of Medicine, Medical College of Virginia/Virginia Commonwealth University School of Medicine, Richmond (K.A.E., J.N.K., R.K.S.); CHU de Toulouse, Toulouse, France (P.M.); and Mount Sinai Hospital, New York, NY (S.R.D., A.d'A.)
| | - Jayanthi N Koneru
- From the Bordeaux University Hospital/LIRYC institute/INSERM 1045/Bordeaux University, Bordeaux, France (F.S., F.P., L.B., P.R., J.C., N.D., A.D., H.C., J.C., M.H., M.H., P.J.); Brigham and Women Hospital, Boston, MA (T.R., S.M., U.T., W.G.S.); Electrophysiology Section, Cardiovascular Division, Hospital of the University of Pennsylvania, Philadelphia (E.S.Z., F.G., F.E.M.); Division of Cardiovascular Medicine, University of Wisconsin Hospital, Madison (M.E.F.); Department of Cardiac Electrophysiology, University of Miami Medical Center, FL (J.F.V.-G., J.O.C.); Institute for Clinical and Experimental Medicine, Prague, Czech Republic (P.P., J.K.); Division of Cardiology, Department of Medicine, Medical College of Virginia/Virginia Commonwealth University School of Medicine, Richmond (K.A.E., J.N.K., R.K.S.); CHU de Toulouse, Toulouse, France (P.M.); and Mount Sinai Hospital, New York, NY (S.R.D., A.d'A.)
| | - Philippe Ritter
- From the Bordeaux University Hospital/LIRYC institute/INSERM 1045/Bordeaux University, Bordeaux, France (F.S., F.P., L.B., P.R., J.C., N.D., A.D., H.C., J.C., M.H., M.H., P.J.); Brigham and Women Hospital, Boston, MA (T.R., S.M., U.T., W.G.S.); Electrophysiology Section, Cardiovascular Division, Hospital of the University of Pennsylvania, Philadelphia (E.S.Z., F.G., F.E.M.); Division of Cardiovascular Medicine, University of Wisconsin Hospital, Madison (M.E.F.); Department of Cardiac Electrophysiology, University of Miami Medical Center, FL (J.F.V.-G., J.O.C.); Institute for Clinical and Experimental Medicine, Prague, Czech Republic (P.P., J.K.); Division of Cardiology, Department of Medicine, Medical College of Virginia/Virginia Commonwealth University School of Medicine, Richmond (K.A.E., J.N.K., R.K.S.); CHU de Toulouse, Toulouse, France (P.M.); and Mount Sinai Hospital, New York, NY (S.R.D., A.d'A.)
| | - Saagar Mahida
- From the Bordeaux University Hospital/LIRYC institute/INSERM 1045/Bordeaux University, Bordeaux, France (F.S., F.P., L.B., P.R., J.C., N.D., A.D., H.C., J.C., M.H., M.H., P.J.); Brigham and Women Hospital, Boston, MA (T.R., S.M., U.T., W.G.S.); Electrophysiology Section, Cardiovascular Division, Hospital of the University of Pennsylvania, Philadelphia (E.S.Z., F.G., F.E.M.); Division of Cardiovascular Medicine, University of Wisconsin Hospital, Madison (M.E.F.); Department of Cardiac Electrophysiology, University of Miami Medical Center, FL (J.F.V.-G., J.O.C.); Institute for Clinical and Experimental Medicine, Prague, Czech Republic (P.P., J.K.); Division of Cardiology, Department of Medicine, Medical College of Virginia/Virginia Commonwealth University School of Medicine, Richmond (K.A.E., J.N.K., R.K.S.); CHU de Toulouse, Toulouse, France (P.M.); and Mount Sinai Hospital, New York, NY (S.R.D., A.d'A.)
| | - Joachim Calderon
- From the Bordeaux University Hospital/LIRYC institute/INSERM 1045/Bordeaux University, Bordeaux, France (F.S., F.P., L.B., P.R., J.C., N.D., A.D., H.C., J.C., M.H., M.H., P.J.); Brigham and Women Hospital, Boston, MA (T.R., S.M., U.T., W.G.S.); Electrophysiology Section, Cardiovascular Division, Hospital of the University of Pennsylvania, Philadelphia (E.S.Z., F.G., F.E.M.); Division of Cardiovascular Medicine, University of Wisconsin Hospital, Madison (M.E.F.); Department of Cardiac Electrophysiology, University of Miami Medical Center, FL (J.F.V.-G., J.O.C.); Institute for Clinical and Experimental Medicine, Prague, Czech Republic (P.P., J.K.); Division of Cardiology, Department of Medicine, Medical College of Virginia/Virginia Commonwealth University School of Medicine, Richmond (K.A.E., J.N.K., R.K.S.); CHU de Toulouse, Toulouse, France (P.M.); and Mount Sinai Hospital, New York, NY (S.R.D., A.d'A.)
| | - Nicolas Derval
- From the Bordeaux University Hospital/LIRYC institute/INSERM 1045/Bordeaux University, Bordeaux, France (F.S., F.P., L.B., P.R., J.C., N.D., A.D., H.C., J.C., M.H., M.H., P.J.); Brigham and Women Hospital, Boston, MA (T.R., S.M., U.T., W.G.S.); Electrophysiology Section, Cardiovascular Division, Hospital of the University of Pennsylvania, Philadelphia (E.S.Z., F.G., F.E.M.); Division of Cardiovascular Medicine, University of Wisconsin Hospital, Madison (M.E.F.); Department of Cardiac Electrophysiology, University of Miami Medical Center, FL (J.F.V.-G., J.O.C.); Institute for Clinical and Experimental Medicine, Prague, Czech Republic (P.P., J.K.); Division of Cardiology, Department of Medicine, Medical College of Virginia/Virginia Commonwealth University School of Medicine, Richmond (K.A.E., J.N.K., R.K.S.); CHU de Toulouse, Toulouse, France (P.M.); and Mount Sinai Hospital, New York, NY (S.R.D., A.d'A.)
| | - Arnaud Denis
- From the Bordeaux University Hospital/LIRYC institute/INSERM 1045/Bordeaux University, Bordeaux, France (F.S., F.P., L.B., P.R., J.C., N.D., A.D., H.C., J.C., M.H., M.H., P.J.); Brigham and Women Hospital, Boston, MA (T.R., S.M., U.T., W.G.S.); Electrophysiology Section, Cardiovascular Division, Hospital of the University of Pennsylvania, Philadelphia (E.S.Z., F.G., F.E.M.); Division of Cardiovascular Medicine, University of Wisconsin Hospital, Madison (M.E.F.); Department of Cardiac Electrophysiology, University of Miami Medical Center, FL (J.F.V.-G., J.O.C.); Institute for Clinical and Experimental Medicine, Prague, Czech Republic (P.P., J.K.); Division of Cardiology, Department of Medicine, Medical College of Virginia/Virginia Commonwealth University School of Medicine, Richmond (K.A.E., J.N.K., R.K.S.); CHU de Toulouse, Toulouse, France (P.M.); and Mount Sinai Hospital, New York, NY (S.R.D., A.d'A.)
| | - Hubert Cochet
- From the Bordeaux University Hospital/LIRYC institute/INSERM 1045/Bordeaux University, Bordeaux, France (F.S., F.P., L.B., P.R., J.C., N.D., A.D., H.C., J.C., M.H., M.H., P.J.); Brigham and Women Hospital, Boston, MA (T.R., S.M., U.T., W.G.S.); Electrophysiology Section, Cardiovascular Division, Hospital of the University of Pennsylvania, Philadelphia (E.S.Z., F.G., F.E.M.); Division of Cardiovascular Medicine, University of Wisconsin Hospital, Madison (M.E.F.); Department of Cardiac Electrophysiology, University of Miami Medical Center, FL (J.F.V.-G., J.O.C.); Institute for Clinical and Experimental Medicine, Prague, Czech Republic (P.P., J.K.); Division of Cardiology, Department of Medicine, Medical College of Virginia/Virginia Commonwealth University School of Medicine, Richmond (K.A.E., J.N.K., R.K.S.); CHU de Toulouse, Toulouse, France (P.M.); and Mount Sinai Hospital, New York, NY (S.R.D., A.d'A.)
| | - Richard K Shepard
- From the Bordeaux University Hospital/LIRYC institute/INSERM 1045/Bordeaux University, Bordeaux, France (F.S., F.P., L.B., P.R., J.C., N.D., A.D., H.C., J.C., M.H., M.H., P.J.); Brigham and Women Hospital, Boston, MA (T.R., S.M., U.T., W.G.S.); Electrophysiology Section, Cardiovascular Division, Hospital of the University of Pennsylvania, Philadelphia (E.S.Z., F.G., F.E.M.); Division of Cardiovascular Medicine, University of Wisconsin Hospital, Madison (M.E.F.); Department of Cardiac Electrophysiology, University of Miami Medical Center, FL (J.F.V.-G., J.O.C.); Institute for Clinical and Experimental Medicine, Prague, Czech Republic (P.P., J.K.); Division of Cardiology, Department of Medicine, Medical College of Virginia/Virginia Commonwealth University School of Medicine, Richmond (K.A.E., J.N.K., R.K.S.); CHU de Toulouse, Toulouse, France (P.M.); and Mount Sinai Hospital, New York, NY (S.R.D., A.d'A.)
| | - Jerome Corre
- From the Bordeaux University Hospital/LIRYC institute/INSERM 1045/Bordeaux University, Bordeaux, France (F.S., F.P., L.B., P.R., J.C., N.D., A.D., H.C., J.C., M.H., M.H., P.J.); Brigham and Women Hospital, Boston, MA (T.R., S.M., U.T., W.G.S.); Electrophysiology Section, Cardiovascular Division, Hospital of the University of Pennsylvania, Philadelphia (E.S.Z., F.G., F.E.M.); Division of Cardiovascular Medicine, University of Wisconsin Hospital, Madison (M.E.F.); Department of Cardiac Electrophysiology, University of Miami Medical Center, FL (J.F.V.-G., J.O.C.); Institute for Clinical and Experimental Medicine, Prague, Czech Republic (P.P., J.K.); Division of Cardiology, Department of Medicine, Medical College of Virginia/Virginia Commonwealth University School of Medicine, Richmond (K.A.E., J.N.K., R.K.S.); CHU de Toulouse, Toulouse, France (P.M.); and Mount Sinai Hospital, New York, NY (S.R.D., A.d'A.)
| | - James O Coffey
- From the Bordeaux University Hospital/LIRYC institute/INSERM 1045/Bordeaux University, Bordeaux, France (F.S., F.P., L.B., P.R., J.C., N.D., A.D., H.C., J.C., M.H., M.H., P.J.); Brigham and Women Hospital, Boston, MA (T.R., S.M., U.T., W.G.S.); Electrophysiology Section, Cardiovascular Division, Hospital of the University of Pennsylvania, Philadelphia (E.S.Z., F.G., F.E.M.); Division of Cardiovascular Medicine, University of Wisconsin Hospital, Madison (M.E.F.); Department of Cardiac Electrophysiology, University of Miami Medical Center, FL (J.F.V.-G., J.O.C.); Institute for Clinical and Experimental Medicine, Prague, Czech Republic (P.P., J.K.); Division of Cardiology, Department of Medicine, Medical College of Virginia/Virginia Commonwealth University School of Medicine, Richmond (K.A.E., J.N.K., R.K.S.); CHU de Toulouse, Toulouse, France (P.M.); and Mount Sinai Hospital, New York, NY (S.R.D., A.d'A.)
| | - Fermin Garcia
- From the Bordeaux University Hospital/LIRYC institute/INSERM 1045/Bordeaux University, Bordeaux, France (F.S., F.P., L.B., P.R., J.C., N.D., A.D., H.C., J.C., M.H., M.H., P.J.); Brigham and Women Hospital, Boston, MA (T.R., S.M., U.T., W.G.S.); Electrophysiology Section, Cardiovascular Division, Hospital of the University of Pennsylvania, Philadelphia (E.S.Z., F.G., F.E.M.); Division of Cardiovascular Medicine, University of Wisconsin Hospital, Madison (M.E.F.); Department of Cardiac Electrophysiology, University of Miami Medical Center, FL (J.F.V.-G., J.O.C.); Institute for Clinical and Experimental Medicine, Prague, Czech Republic (P.P., J.K.); Division of Cardiology, Department of Medicine, Medical College of Virginia/Virginia Commonwealth University School of Medicine, Richmond (K.A.E., J.N.K., R.K.S.); CHU de Toulouse, Toulouse, France (P.M.); and Mount Sinai Hospital, New York, NY (S.R.D., A.d'A.)
| | - Meleze Hocini
- From the Bordeaux University Hospital/LIRYC institute/INSERM 1045/Bordeaux University, Bordeaux, France (F.S., F.P., L.B., P.R., J.C., N.D., A.D., H.C., J.C., M.H., M.H., P.J.); Brigham and Women Hospital, Boston, MA (T.R., S.M., U.T., W.G.S.); Electrophysiology Section, Cardiovascular Division, Hospital of the University of Pennsylvania, Philadelphia (E.S.Z., F.G., F.E.M.); Division of Cardiovascular Medicine, University of Wisconsin Hospital, Madison (M.E.F.); Department of Cardiac Electrophysiology, University of Miami Medical Center, FL (J.F.V.-G., J.O.C.); Institute for Clinical and Experimental Medicine, Prague, Czech Republic (P.P., J.K.); Division of Cardiology, Department of Medicine, Medical College of Virginia/Virginia Commonwealth University School of Medicine, Richmond (K.A.E., J.N.K., R.K.S.); CHU de Toulouse, Toulouse, France (P.M.); and Mount Sinai Hospital, New York, NY (S.R.D., A.d'A.)
| | - Usha Tedrow
- From the Bordeaux University Hospital/LIRYC institute/INSERM 1045/Bordeaux University, Bordeaux, France (F.S., F.P., L.B., P.R., J.C., N.D., A.D., H.C., J.C., M.H., M.H., P.J.); Brigham and Women Hospital, Boston, MA (T.R., S.M., U.T., W.G.S.); Electrophysiology Section, Cardiovascular Division, Hospital of the University of Pennsylvania, Philadelphia (E.S.Z., F.G., F.E.M.); Division of Cardiovascular Medicine, University of Wisconsin Hospital, Madison (M.E.F.); Department of Cardiac Electrophysiology, University of Miami Medical Center, FL (J.F.V.-G., J.O.C.); Institute for Clinical and Experimental Medicine, Prague, Czech Republic (P.P., J.K.); Division of Cardiology, Department of Medicine, Medical College of Virginia/Virginia Commonwealth University School of Medicine, Richmond (K.A.E., J.N.K., R.K.S.); CHU de Toulouse, Toulouse, France (P.M.); and Mount Sinai Hospital, New York, NY (S.R.D., A.d'A.)
| | - Michel Haissaguerre
- From the Bordeaux University Hospital/LIRYC institute/INSERM 1045/Bordeaux University, Bordeaux, France (F.S., F.P., L.B., P.R., J.C., N.D., A.D., H.C., J.C., M.H., M.H., P.J.); Brigham and Women Hospital, Boston, MA (T.R., S.M., U.T., W.G.S.); Electrophysiology Section, Cardiovascular Division, Hospital of the University of Pennsylvania, Philadelphia (E.S.Z., F.G., F.E.M.); Division of Cardiovascular Medicine, University of Wisconsin Hospital, Madison (M.E.F.); Department of Cardiac Electrophysiology, University of Miami Medical Center, FL (J.F.V.-G., J.O.C.); Institute for Clinical and Experimental Medicine, Prague, Czech Republic (P.P., J.K.); Division of Cardiology, Department of Medicine, Medical College of Virginia/Virginia Commonwealth University School of Medicine, Richmond (K.A.E., J.N.K., R.K.S.); CHU de Toulouse, Toulouse, France (P.M.); and Mount Sinai Hospital, New York, NY (S.R.D., A.d'A.)
| | - Andre d'Avila
- From the Bordeaux University Hospital/LIRYC institute/INSERM 1045/Bordeaux University, Bordeaux, France (F.S., F.P., L.B., P.R., J.C., N.D., A.D., H.C., J.C., M.H., M.H., P.J.); Brigham and Women Hospital, Boston, MA (T.R., S.M., U.T., W.G.S.); Electrophysiology Section, Cardiovascular Division, Hospital of the University of Pennsylvania, Philadelphia (E.S.Z., F.G., F.E.M.); Division of Cardiovascular Medicine, University of Wisconsin Hospital, Madison (M.E.F.); Department of Cardiac Electrophysiology, University of Miami Medical Center, FL (J.F.V.-G., J.O.C.); Institute for Clinical and Experimental Medicine, Prague, Czech Republic (P.P., J.K.); Division of Cardiology, Department of Medicine, Medical College of Virginia/Virginia Commonwealth University School of Medicine, Richmond (K.A.E., J.N.K., R.K.S.); CHU de Toulouse, Toulouse, France (P.M.); and Mount Sinai Hospital, New York, NY (S.R.D., A.d'A.)
| | - William G Stevenson
- From the Bordeaux University Hospital/LIRYC institute/INSERM 1045/Bordeaux University, Bordeaux, France (F.S., F.P., L.B., P.R., J.C., N.D., A.D., H.C., J.C., M.H., M.H., P.J.); Brigham and Women Hospital, Boston, MA (T.R., S.M., U.T., W.G.S.); Electrophysiology Section, Cardiovascular Division, Hospital of the University of Pennsylvania, Philadelphia (E.S.Z., F.G., F.E.M.); Division of Cardiovascular Medicine, University of Wisconsin Hospital, Madison (M.E.F.); Department of Cardiac Electrophysiology, University of Miami Medical Center, FL (J.F.V.-G., J.O.C.); Institute for Clinical and Experimental Medicine, Prague, Czech Republic (P.P., J.K.); Division of Cardiology, Department of Medicine, Medical College of Virginia/Virginia Commonwealth University School of Medicine, Richmond (K.A.E., J.N.K., R.K.S.); CHU de Toulouse, Toulouse, France (P.M.); and Mount Sinai Hospital, New York, NY (S.R.D., A.d'A.)
| | - Francis E Marchlinski
- From the Bordeaux University Hospital/LIRYC institute/INSERM 1045/Bordeaux University, Bordeaux, France (F.S., F.P., L.B., P.R., J.C., N.D., A.D., H.C., J.C., M.H., M.H., P.J.); Brigham and Women Hospital, Boston, MA (T.R., S.M., U.T., W.G.S.); Electrophysiology Section, Cardiovascular Division, Hospital of the University of Pennsylvania, Philadelphia (E.S.Z., F.G., F.E.M.); Division of Cardiovascular Medicine, University of Wisconsin Hospital, Madison (M.E.F.); Department of Cardiac Electrophysiology, University of Miami Medical Center, FL (J.F.V.-G., J.O.C.); Institute for Clinical and Experimental Medicine, Prague, Czech Republic (P.P., J.K.); Division of Cardiology, Department of Medicine, Medical College of Virginia/Virginia Commonwealth University School of Medicine, Richmond (K.A.E., J.N.K., R.K.S.); CHU de Toulouse, Toulouse, France (P.M.); and Mount Sinai Hospital, New York, NY (S.R.D., A.d'A.)
| | - Pierre Jais
- From the Bordeaux University Hospital/LIRYC institute/INSERM 1045/Bordeaux University, Bordeaux, France (F.S., F.P., L.B., P.R., J.C., N.D., A.D., H.C., J.C., M.H., M.H., P.J.); Brigham and Women Hospital, Boston, MA (T.R., S.M., U.T., W.G.S.); Electrophysiology Section, Cardiovascular Division, Hospital of the University of Pennsylvania, Philadelphia (E.S.Z., F.G., F.E.M.); Division of Cardiovascular Medicine, University of Wisconsin Hospital, Madison (M.E.F.); Department of Cardiac Electrophysiology, University of Miami Medical Center, FL (J.F.V.-G., J.O.C.); Institute for Clinical and Experimental Medicine, Prague, Czech Republic (P.P., J.K.); Division of Cardiology, Department of Medicine, Medical College of Virginia/Virginia Commonwealth University School of Medicine, Richmond (K.A.E., J.N.K., R.K.S.); CHU de Toulouse, Toulouse, France (P.M.); and Mount Sinai Hospital, New York, NY (S.R.D., A.d'A.)
| |
Collapse
|
50
|
|